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ABSTRACT 
Catherine C. Fahey: The effect of cancer-associated SETD2 mutations on transcription and chromatin 
organization 
(Under the direction of W. Kimryn Rathmell and Ian J. Davis) 
 
Clear cell renal cell carcinoma is characterized by mutations in chromatin modifying enzymes. 
Among these is SETD2, a non-redundant histone H3 lysine 36 methyltransferase. Mutations in SETD2 in 
ccRCC are either early-inactivating, occur in the catalytic SET domain, or are found in the Set2 Rpb1-
interacting domain. We inactivated SETD2 in ccRCC cells lines and reintroduced a truncated but functional 
wildtype SETD2 (tSETD2), as well as three ccRCC-associated point mutations in order to examine the 
effect on DNA damage repair, chromatin organization, transcription, and H3K36 trimethylation. We found 
that SETD2 loss results in complete loss of H3K36me3. SETD2Δ cells do not resolve γH2A.X foci after 
DNA damage and show altered chromatin accessibility. Transcription is largely unaffected by SETD2 loss. 
tSETD2 restores H3K36me3 to loci marked by H3K36me3 in wildtype cells, indicating that the N-terminus 
of SETD2 in not required for H3K36me3 placement. The first examined point mutant, R1625C, occurs in 
the SET domain and disrupts catalytic activity of SETD2 by reducing the interaction between SETD2 and 
histone H3, which results in decreased protein stability in the cell. The second examined point mutation, 
R2510H, occurs in the SRI domain. This SRI domain mutant is catalytically active. The third mutation, 
T2457*, deletes the SRI domain from tSETD2, and is also catalytically active. Both the R2510H and the 
T2457* mutations disrupt the interaction between SETD2 and RNA polymerase II. Surprisingly, both of 
these mutants also restore H3K36me3 to loci marked by wildtype SETD2. These mutants also show 
increased H3K36me3 levels near the TSS relative to wildtype. This suggests that the SRI domain is 
necessary for interaction with RNAPII, is not required for normal H3K36me3 placement across the genome, 
and may be involved at the TSS for H3K36me3 marking. The separation of function for the SET and SRI 
domains is of important consideration when developing therapeutics which target SETD2 mutation in 
ccRCC.   
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CHAPTER 1: SETting the stage for cancer development - SETD2 and the consequences of lost 
methylation1 
 
1.1 Enzymatic function and structure of SETD2
SETD2 (also known as HYPB or KMT3a) is the sole human methyltransferase that mediates 
trimethylation of histone H3.1 and H3 variants (Figure 1.1) [1]. Although SETD2 demonstrates biochemical 
evidence of mono- and dimethylation activity, in cells it seems to exclusively mediate trimethylation since 
SETD2 silencing results in a near complete loss of H3K36 trimethylation without decreasing mono- or 
dimethylation levels [1,2]. In higher eukaryotes, other enzymes, including NSD1, WHSC1 (NSD2) and 
SETMAR, are able to mono- and dimethylate H3K36 (reviewed in [3]). In contrast, the homolog of SETD2 
in Saccharomyces cerevisiae, Set2, exclusively mediates all H3K36 methylation states [4]. Although 
extensive genetic experimentation with yeast Set2 has informed our understanding of the biochemical 
properties of critical SETD2 domains as well as the possible roles, the redundancy of mono- and 
dimethylation activities in humans offers an important caveat when extrapolating results from S. cerevisiae.  
The functions of SETD2 have been attributed to several domains in the protein (Figure 1.2). These 
domains share sequence homology as well as functional similarity with those in yeast Set2. The 
methyltransferase activity is mediated by the conserved SET domain [4,5].  SETD2 contains two known 
                                                     
1This research was originally published in Cold Spring Harbor Perspectives. Fahey CC, Davis IJ. SETting 
the stage for cancer development: SETD2 and the consequences of lost methylation. Cold Spring Harbor 
Perspectives. 2017; 1–16. doi: 10.1101/CSHPERSPECT.a026468.  
Figure 1.1: H3K36me3 methyltransferases. Methyltransferases shown to mono-, di-, and trimethylate H3K36. 
Those shown in bold have been shown in cell based assays and/or in vivo. Adapted from [3] 
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protein binding domains: SRI (Set2 Rpd1 Interacting) and WW. The SRI domain mediates association with 
the hyperphosphorylated C-terminal domain (CTD) of RNA polymerase II (RNAPII) [5–7]. In yeast, this 
interaction is required for H3K36 activity, as deletion of the RNAPII CTD decreases H3K36 methylation 
levels [7,8]. The WW domain, which precedes the SRI domain, may mediate intramolecular interaction [9]. 
Based on the property of WW domain interaction with phosphorylated proteins, this domain could also 
mediate other protein interactions [10]. About half of SETD2 consists of a large amino terminal domain that 
is not shared by yeast Set2 and is of unknown function. 
1.2 SETD2 mutation in cancer 
Hundreds of distinct SETD2 mutations have been identified across a wide range of human tumors, 
including epithelial, CNS and hematopoietic (Table 1.1, Figure 1.2) [11,12]. SETD2 mutation was first 
described in clear cell renal cell carcinoma (ccRCC). In a cohort of 407 ccRCC tumors, truncating mutations 
were observed in twelve samples [13]. SETD2 mutation was also found in ccRCC cell lines [14]. In The 
Cancer Genome Atlas (TCGA) study of ccRCC, SETD2 was the third most commonly mutated gene with a 
prevalence of 15.6%. SETD2 is located on chromosome 3p, which demonstrates near universal loss of 
heterozygosity in ccRCC [15]. Chromosome 3p is also the location of the well-known tumor suppressor 
Figure 1.2: Schematic representation of SETD2 and cancer-associated mutations. SETD2 domains: AWS 
(Associated with SET), SET (Su(var)3-9, Enhancer-of-zeste, Trithorax), PS (Post-SET), CC (Coiled Coil), 
LCR (Low Charge Region), WW, SRI (Set2 Rpb1 Interacting). Mutation lists were obtained from CBioPortal 
on February 5th, 2016, and separated into cancer types. Duplicates were removed. Mutations are plotted 
by color (cancer type) and shape (mutation type). Abbreviations: Clear cell renal cell carcinoma (ccRCC) 
and Papillary renal cell carcinoma (pRCC). 
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VHL. VHL expression is lost in most cases of sporadic ccRCC, and germline mutation is associated with a 
high penetrance of ccRCC [16]. Mutations of SETD2 affect the remaining allele, and frequently have a 
significant impact on gene function. Most mutations tend to be inactivating frameshift or nonsense 
mutations, although missense mutations in critical domains have been detected [17–20]. In a study of 128 
sporadic ccRCC tumors that specifically examined genes known to be mutated in ccRCC, SETD2 was 
mutated in approximately 16% [19].  Five frameshift, ten nonsense, two splice site mutations were 
observed. Of three nonsynonymous missense mutations, one altered the SET domain [19]. Studies of 
intratumoral genetic heterogeneity also support a key role for SETD2 loss. Sequencing multiple sites in a 
single kidney tumor together with metastatic sites identified multiple distinct SETD2 mutations each likely 
to disrupt function. This convergent tumor evolution suggests that SETD2 mutation is a critical event for a 
subset of ccRCCs [20]. Suggestive of a link with aggressive disease, a lower level of H3K36 trimethylation  
was observed in metastases compared with primary tumors [21].  
 SETD2 mutations have also been identified in multiple other cancers. High severity SETD2 
mutation was observed in 15-28% of pediatric and 8% of adult high-grade gliomas (HGG) [22]. In contrast, 
SETD2 mutations were not identified in low-grade gliomas. In addition, all tumors with SETD2 mutation 
were located in the cerebral hemispheres [22]. However, mutation of SETD2 was detected in a single 
Table 1.1: Cancers associated with SETD2 mutation. Cancers were selected for which the mutation rate in 
CBioPortal [11,12] (accessed on June 14th, 2016) exceeded 5% and a publication was available. Indicated 
mutation rate reflects published results. Additional cancers discussed in the text were also included.   
Cancer Type Mutation % (total samples) Reference 
Clear cell renal cell carcinoma 15.6% (418 samples) [18] 
High Grade Glioma 15% (543 samples) [22] 
Uterine Carcinosarcoma 
Uterine Corpus Endometrioid Carcinoma 
13.6% (22 samples) 
9% (240 samples) 
[23] 
[24] 
Acute Lymphocytic Leukemia 12% (125 samples) 
10% (94 samples) 
[25] 
[26] 
Bladder Urothelial Carcinoma 10.2% (107 samples) 
6% (50 samples) 
[27] 
[28] 
Desmoplastic Melanoma 
Melanoma 
Cutaneous Melanoma 
10% (20 samples) 
8% (25 samples) 
5.5% (91 samples) 
[29] 
[30] 
[31] 
Lung Adenocarcinoma 9% (230 samples) 
5.5% (182 samples) 
[32] 
[33] 
Colorectal Adenocarcinoma 8.3% (72 samples) 
6.1%, (212 samples) 
[34] 
[35] 
Pancreatic Adenocarcinoma 8.3% (109 samples) [36] 
Stomach Adenocarcinoma 7% (287 samples) [37] 
Papillary renal cell carcinoma 7.6% (157 samples) [38] 
Cutaneous squamous cell carcinoma 6.9% (29 samples) [39] 
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diffuse intrinsic pontine glioma, although it co-occurred with an H3.1 K27M mutation, a common feature of 
these tumors [40]. Intriguingly, high grade hemispheric gliomas of children and young adults are also 
commonly associated with mutation of histone H3.3 (H3F3A) at glycine 34 [41,42]. These mutations were 
non-overlapping with SETD2 and were associated with reduced H3K36 methylation [22,41,43]. Gliomas 
also commonly harbor IDH1 mutations, which result in the generation of the 2-hydroxyglutarate (2-HG) 
oncometabolite [44]. These mutations are not mutually exclusive with SETD2 mutation. Although 2-HG 
inhibits histone demethylases, including those that can act on H3K36, it is not clear if IDH1 mutation directly 
affects H3K36me3 [22,45–47]. Overall, these findings indicate that dysregulation of H3K36me3 is a 
common event in glioma. The finding linking H3.3 mutation with reduced H3K36 methylation will be 
discussed in more detail below. 
SETD2 mutations have also been identified in acute leukemias. In a study of early T-cell precursor 
acute lymphoblastic leukemia (ETP-ALL), approximately 10% demonstrated deletion or high severity 
mutation of SETD2 [26]. In a separate study, SETD2 mutation was detected in approximately 6% of ALL 
and AML samples [48]. Mutation of SETD2 was more common in both acute lymphoid and myeloid 
leukemias with MLL-rearrangement compared to ALL and AML with an intact MLL gene. Further supporting 
SETD2 loss as a critical event in leukemia development, SETD2 mutations were commonly nonsense or 
frameshift, and approximately a quarter of samples carried biallelic SETD2 mutations [48]. A comparison 
of matched primary and relapsed ALL samples suggested that mutations in epigenetic regulators as a class 
were more common at relapse, and this included mutations in SETD2 [25]. In this study, SETD2 
demonstrated a mutation rate of 5% in a pilot cohort and 12% in a larger validation set. The validation set 
contained a higher fraction of MLL-rearranged samples possibly explaining the discrepancy in mutation 
frequency. Suggesting that the importance of SETD2 mutation is greater in acute leukemias in children, the 
study of AML by TCGA identified only a single SETD2 mutation among 191 adult samples [49]. The link 
between SETD2 loss and MLL rearrangement is provocative since, like SETD2, MLL fusion proteins can 
associate with components of the transcriptional complex, and the combined alterations in these proteins 
may lead to transcriptional dysregulation [50,51].  
SETD2 mutations have also been observed at a low frequency in a range of other tumors. 6% of 
melanoma and chronic lymphocytic leukemia demonstrated SETD2 alteration [30,52,53]. SETD2 
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alterations were observed in high-risk, but not low-risk, gastrointestinal stromal tumors [54]. SETD2 
mutation has also been described in phyllodes tumors of the breast, but not in breast fibroadenoma [55,56]. 
Among other genitourinary tumors, SETD2 mutation is found in 10% of bladder tumors and the papillary 
subtype of renal cell carcinoma [27,38]. Although many of these mutations are monoallelic and 
consequently predicted to lead to haploinsufficiency, mutations are not the exclusive mechanism for 
modulating SETD2 activity.  
Decreased H3K36me3 has also been observed in the context of non-mutant SETD2 in ccRCC [17]. 
miR-106b-5p, a micro RNA known to regulate SETD2, was elevated in a cohort of 40 ccRCC tumor 
samples; levels of this miRNA inversely correlated with SETD2 mRNA and protein levels [57]. SETD2 
mRNA levels were also decreased in a subset of patients with AML and lymphoma [48]. 
In addition to alterations in SETD2, H3K36me3 can be lost by mutation of the methyl acceptor site 
in histones or by mutations in neighboring amino acids. Virtually all chondroblastomas harbor a lysine 36 
to methionine variant in histone H3.3 (H3.3K36M) [58]. Expression of the H3.3K36M mutant in cells led to 
depletion of all H3K36 trimethylation [59]. H3.3K36M binds and directly inhibits the activity of SETD2 and 
the dimethylation activity of MMSET [60]. Mutations in H3.3 at the neighboring G34 residue have been 
described in almost all giant cell bone tumors [58] and, as previously mentioned, in high grade gliomas 
[40,41].  Overall, the common finding of loss or inhibition of SETD2 across a wide range of cancers suggests 
the importance of disrupted H3K36 methylation in cancer development.  
1.3 Transcription and RNA splicing 
Chromatin influences many cellular processes including transcription, replication and DNA damage 
repair. Many studies have linked SETD2 and transcription. In yeast, Set2 and H3K36 trimethylation are 
associated with gene bodies, and H3K36me3 levels correlate both with the level of transcription and the 
position in the gene [61,62]. H3K36me3 signals are enriched at exons, although the higher levels of 
nucleosome occupancy at exons may explain this difference [63]. Treatment with a transcription inhibitor 
causes a decrease in H3K36me3 levels [64], suggesting that active transcription is necessary for 
H3K36me3 placement.  These data are consistent with the model that Set2 and SETD2 are targeted to 
elongating RNAPII. 
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Our understanding of the role of SETD2 in transcription is largely based on studies of Set2 in yeast. 
In yeast, Set2 partially functions to prevent cryptic initiation, aberrant transcription from internal sites. H3K36 
methylation recruits the Rpd3C(S) complex, which includes a histone deacetylase [65,66], leading to the 
deacetylation of histones in gene bodies. H3K36 methylation also suppresses of the interaction between 
histone H3 and the histone chaperone Asf1 [67]. Preventing the incorporation of new acetylated histones 
maintains a hypoacetylated state, thereby stabilizing nucleosomes which decreases the chance of a 
segment of gene being aberrantly recognized by the transcriptional initiation complex as a promoter 
[65,68,69].  
The role of SETD2 in transcription in higher eukaryotes is more complicated. In addition to the 
separation of methylation activities across multiple enzymes, genes in higher eukaryotes contain introns 
and are regulated by alternative splicing, and DNA itself can be methylated. H3K36 methylation levels differ 
based on exon utilization [70], with alternatively spliced exons having lower levels of H3K36me3 than those 
that are constitutively included. Altering SETD2 levels influenced the inclusion of exons in genes known to 
be alternatively spliced [71]. Deletion of the splice acceptor site in the β-globin intron leads to shifts in 
H3K36me3 signal [72], and intronless genes have lower levels of H3K36 trimethylation [64]. Chemical or 
RNAi mediated inhibition of splicing decreased H3K36me3 levels. Together these data suggest a close 
relationship between trimethylation of H3K36 and RNA splicing. Perhaps reflecting aberrant transcription 
or RNA processing, silencing SETD2 results in mRNA accumulation in the nucleus [73].  
Several studies have explored the impact of SETD2 loss on transcription in kidney cancer. 
Examining primary ccRCC, H3K36me3 deficient tumors show alterations in splicing and evidence of intron 
retention [17]. This association was also detected in transcriptomic ccRCC data from TCGA. Similarly, 
differential splicing and altered exon utilization was observed in SETD2 knockout cells [21]. However, no 
difference in exon usage or intron retention was observed in other studies in which SETD2 was silenced 
using RNAi [74]. SETD2 has also been associated with aberrant transcriptional termination [75]. In the 
absence of appropriate termination, RNAPII complexes can read through into neighboring genes yielding 
in chimeric RNAs. 
Several proteins that bind H3K36 methylation offer a link between SETD and RNA splicing (Figure 
1.3).  LEDGF (PSIP1) exists as two isoforms, p52 and p75, based on the inclusion of six additional 3’ exons 
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[76].  Both forms contain a PWWP domain which interacts with di- and trimethylated H3K36. The short form, 
LEDGF/p52, interacts with proteins involved in alternative splicing [77]. ZMYND11, also a PWWP domain 
containing protein, binds H3.3K36 and associates with regulators of RNA splicing [78]. MRG15 is a 
chromodomain containing protein that binds di- and trimethylated H3K36 [79] and recruits polypyrimidine 
tract-binding protein (PTB) to alternatively spliced exons [71]. PTB then binds to silencing elements causing 
repression of specific exons.  
In embryonic stem cells, MRG15 also recruits the lysine demethylase KDM5B to H3K36me3 
marked chromatin [80]. Silencing KDM5B resulted in recruitment of unphosphorylated RNAPII to intragenic 
regions marked by H3K4me3, potential sites of cryptic initiation. Knockdown of KDM5B increased levels of 
unspliced transcripts, possibly reflecting aberrant transcription.  Downregulation of SETD2 was also found 
to be associated with increased RNA abundance at non-initiating exons, potentially indicating 
transcriptional initiation from these sites [81]. Taken together, the extent to which cryptic initiation in yeast 
is a function of dimethylation (rather than trimethylation) or that RNA alteration in higher eukaryotic cells 
results from aberrant splicing (rather than cryptic initiation) are unknown.  
Overall, SETD2-mediated histone modification and its interaction with specific binding partners 
offers an explanation for the variation in transcription and aberrant RNA detected after SETD2 loss. 
Although intron retention has been showed to be a mechanism of tumor-suppressor inactivation [82], how 
SETD2 loss facilitates tumor development remains unknown.  
Figure 1.3: Transcription and RNA processing. SETD2 associates with RNAPII to post translationally modify 
nucleosomes. H3K36me3 is directly bound by readers which mediate RNA processing through downstream 
effectors. 
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1.4 Chromatin structure 
Several studies have shown that H3K36me3 loss results in alterations in chromatin architecture. 
Silencing SETD2 impairs the recruitment of the FACT (Facilitates Chromatin Transcription) complex to 
transcribed chromatin which results in increased sensitivity to MNase digestion, suggesting alteration in 
nucleosomal interaction with DNA [81]. This effect was particularly evident at internal exons. Chromatin 
alterations in response to SETD2 silencing was also observed in a kidney cancer cell line [74]. A similar 
observation was made by examining chromatin accessibility in H3K36me3-deficient primary renal cell 
carcinomas using formaldehyde assisted isolation of regulatory elements (FAIRE) [17]. Overall, enhanced 
accessibility corresponded to regions typically marked by H3K36me3. By examining individual genic 
features, signal increases were most striking immediately preceding exons, suggestive of a specific effect 
at splice acceptor sites.  Together, these studies support a link between SETD2, chromatin accessibility 
and splicing.  
1.5 DNA replication and damage repair 
Substantial evidence supports the involvement of SETD2 and H3K36 methylation in DNA damage 
repair by homologous recombination (HR) (Figure 1.4). SETD2 silencing resulted in a loss of HR at 
experimentally induced sites of double-strand breaks (DSB) [83]. In particular, SETD2 loss decreased levels 
of ATM phosphorylation and consequently p53 phosphorylation [84] with decreased levels of p53 
transcriptional targets [84,85]. SETD2 has been shown to associate with and potentially stabilize p53, which 
may partially account for the difference in transcriptional targets [85]. SETD2 loss was also associated with 
decreased recruitment of the HR proteins 53BP1, RPA and RAD51 to chromatin [74,83,86]. This effect 
seems to be mediated by the histone methylation activity of SETD2 since reintroduction of a catalytically 
dead SETD2 mutant failed to rescue RPA or RAD51 foci formation, and depletion of H3K36me3 by 
overexpression of the KDM4 demethylase or H3.3K36M also delayed RAD51 foci formation [86].   
LEDGF may bridge H3K36 methylation and the DNA damage response mechanism. In contrast to 
the role of the p52 isoform in transcription, the LEDGF/p75 isoform recruits C-terminal binding protein 
interacting protein (CtIP) to sites of DNA damage [87]. CtIP processes DNA ends to enable binding of 
RAD51 (reviewed in [88]).  Depletion of SETD2 results in decreased LEDGF bound to chromatin, reduced 
CtIP recruitment to DSB and levels of single stranded DNA near the DSB, suggesting impaired resection 
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[86]. This suggests a model in which regions marked by H3K36me3 by SETD2 are bound by LEDGF 
following DSB, leading to recruitment of CtIP and RAD51, and ultimately repair by HR. Whether SETD2 is 
recruited to sites of DNA damage that will go on to repair by homologous recombination, or conversely, that 
homologous recombination is more likely at regions already marked by H3K36me3 remains unclear. In 
contrast to H3K36me3, H3K36me2 is rapidly induced after irradiation (Fnu et al., 2011). Increased levels 
of early non-homologous end joining (NHEJ) factors were detected by immunoprecipitation of H3K36me2 
following radiation.  
In addition to HR, SETD2 is involved in mismatch repair (MMR) (Figure 1.4).  hMSH6, a component 
of the hMutSα complex that recognizes mismatches in the genome, also contains a PWWP domain that 
mediates interaction with methylated H3K36 [89]. SETD2 silencing or overexpression of KDM4 decreased 
MSH6 foci formation associated with increased microsatellite instability (MSI) [89,90]. However, ccRCC 
tumors samples with biallelic SETD2 loss did not exhibit classic findings of MSI, increased breakpoints or 
a substantially increased mutation load, compared with tumor cells with monoallelic loss [74]. DNA breaks 
identified in tumors with monoalleic SETD2 loss demonstrated significantly lower levels of H3K36me3. 
Figure 1.4: DNA damage repair. Specific H3K36me3 readers direct either homologous recombination (top) 
or mismatch repair (bottom). 
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These data are consistent with the model that H3K36me3 marked sites are protected from breakage. Taken 
together, these studies suggest that H3K36 methylation functions in DNA damage repair with methylation 
status biasing towards different repair pathways, with dimethylation favoring NHEJ and trimethylation 
favoring HR and MMR. Although SETD2 deficient kidney cancers are not characterized by increased 
mutational level, it remains possible that intratumoral heterogeneity limits our ability to detect this feature 
[20].   
1.6 DNA methylation and replication 
 Alterations in DNA methylation have been linked to SETD2 and H3K36me3 loss. The DNA 
methyltransferases DNMT3A and DNMT3B contain a PWWP domain enabling binding to methylated 
H3K36 [91,92]. DNMT3B was enriched at H3K36me3 marked gene bodies, and SETD2 knockout reduced 
DNMT3B binding [92]. In this study, SETD2 loss was associated with decreased de novo DNA methylation, 
although a separate study did not observe this association [93]. Alterations in DNA methylation correlated 
with SETD2 loss have been demonstrated in ccRCC. In the TCGA analysis, SETD2 mutation was 
associated with decreased DNA methylation at regions that are normally marked by H3K36me3 in kidney 
[18]. Increased chromatin accessibility was also associated with regions of DNA hypomethylation in SETD2 
mutant tumors [17]. SETD2 loss has also been associated with increased DNA methylation at intergenic 
regions [94]. Overall, these data suggest that H3K36me3 directs DNA methyltransferases to gene bodies 
but in the absence of this histone modification, methylation increases elsewhere.  
H3K36me3 levels are cell cycle regulated with a peak in early S phase then declining to low levels 
that persist during G2/M [89]. This pattern suggests that SETD2 is most active during DNA replication. In 
support of a role during replication, depletion of SETD2 in kidney cancer cells slowed replication fork 
progression and led to an accumulation of cells in S phase [74]. However, in isogenic SETD2 knockout cell 
lines cell cycle differences were not observed [95]. 
1.7 SETD2 in cancer development and therapeutics 
How SETD2 loss results in cancer development remains unknown. However, several studies have 
linked H3K36 methylation to aberrant differentiation or proliferation. SETD2 loss disrupts murine embryonic 
stem cell differentiation, possibly by altering intracellular signaling [96]. Expression of H3.3 mutants that 
inhibit H3K36 methylation in chondrocytes and mesenchymal progenitor cells disrupted differentiation 
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[60,97]. Mouse mesenchymal progenitor cells (MPCs) that stably express either wild-type or K36M mutant 
H3.3 formed tumors after subcutaneous injection in immunocompromised mice [97]. In renal primary 
epithelial tubule cells, cells considered to be the proposed progenitor for ccRCC, SETD2 knockdown 
resulted in continued proliferation well past the point at which these cells typically senesce [98]. In models 
of MLL-rearranged leukemia, SETD2 loss is associated with increased colony formation, proliferation and 
accelerated leukemia development after transplantation [48]. Taken together, these studies support a role 
of SETD2 in facilitating faithful differentiation. Interestingly, germline mutations in SETD2 as well as NSD1 
(the H3K36 dimethylase, see Figure 1.1) have been associated with Sotos and Sotos-like overgrowth 
syndromes [99–101]. Sotos syndrome has been associated with an increased frequency of malignancy, 
particularly acute leukemias and lymphomas, Wilms tumor and neuroblastoma (reviewed in [102]). 
The clinical implications of SETD2 loss in cancer have primarily focused on ccRCC. SETD2 
mutation is associated with worse cancer specific survival in the TCGA dataset [103]. Additionally, SETD2 
mutation was a univariate predicator of time to recurrence, and was found at higher percentages in late 
stage tumors. Tumors with any of BAP1, SETD2 or KDM5C mutation were more likely to present with 
advanced stage [104]. In metastatic RCC, low SETD2 expression was associated with reduced overall and 
progression free survival, and was an independent prognostic marker for these endpoints [105]. SETD2 
expression was lower in breast tumors, compared with matched normal tissue [106,107], with expression 
inversely correlated with increasing tumor stage [107]. In these patients, SETD2 mRNA levels were lower 
in patients with poor outcomes, such metastasis, local recurrence and cancer-specific death. 
Several studies have explored whether SETD2 loss sensitizes tumor cells to targeted agents. 
TGX221, a selective PI3Kb inhibitor, was selectively toxic to RCC cells that were mutant for both VHL and 
SETD2, whereas cells lacking either mutation were not sensitive [108]. Treatment with this compound 
resulted in decreased migration and invasion of mutant cell lines. Employing a synthetic lethality screening 
strategy, H3K36me3-deficient cell lines were found to be sensitive to WEE1 inhibition [95]. The proposed 
target of this synthetic lethal interaction is RRM2, a ribonucleotide reductase subunit. SETD2 deficiency 
and WEE1 inhibition each decreased RRM2 levels, and the combination resulted in further depletion. WEE1 
inhibition in the context of SETD2 deficiency critically reduces the dNTP pool causing cells to accumulate 
in non-replicating S-phase, replication stress and cell death.  
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1.8 Non-histone targets 
Although the focus of SETD2 research has been primarily on histone regulation, it is possible that 
SETD2 may have important non-histone targets. Recently, it has been reported that SETD2 targets tubulin 
for modification [109]. SETD2 methylates α-tubulin at lysine 40, which can also be acetylated on 
microtubules. This methylation occurs during mitosis and cytokinesis. When SETD2 is deleted, mitotic 
spindle and cytokinetic defects occur, as well as micronuclei formation and polyploidy. This suggests that 
SETD2 has function both in the nucleus and the cytoplasm, and may contribute to cancer development by 
multiple mechanisms. 
1.9 Concluding Remarks and contributions of this work 
Large sequencing studies have increasingly implicated mutations in epigenetic modifiers as critical 
events in cancer development and have identified SETD2 loss as a key feature of multiple types of cancer. 
SETD2 has been implicated in many chromatin-directed nuclear processes, including transcriptional 
regulation, DNA damage repair, DNA methylation and replication. These effects are likely mediated by 
H3K36me3 binding reader proteins. Consequently, shifts in H3K36 di- and trimethylation are expected to 
lead to loss of appropriate reader targeting or redistribution. The relative importance of the H3K36-
associated functions to cancer development remains unclear. As SETD2 mutation is associated with more 
aggressive cancer, it is important to fully understand the effect of SETD2 loss on oncogenesis. 
Vulnerabilities created by SETD2 through deregulated transcription and DNA replication may offer 
therapeutic strategies. The work described in this dissertation furthers our understanding of how SETD2 
mutations alter activity.  
 Chapter 2 describes work exploring the effect of specific SETD2 mutations on H3K36me3 and DNA 
damage in both yeast and human cells. First, we establish the similarities between human SETD2 and 
yeast Set2 by sequence and structure, and identify clear cell renal cell carcinoma mutations for further 
study. We then introduce these mutations into SETD2Δ human cells and Set2Δ yeast cells to characterize 
the effect of mutation on known functions. We show that H3K36me3 is required for DNA damage repair in 
human cells, while H3K36me2 is sufficient for studied yeast phenotypes. 
 In Chapter 3, we identify the effect of SETD2 inactivation on a genomic level, by examining changes 
in RNA levels through RNA-seq, chromatin organization by FAIRE-seq, and nucleosome positioning by 
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MNase-seq. Chapter 4 examines the effect of specific ccRCC-associated SETD2 mutations on H3K36me3 
levels using chromatin immunoprecipitation sequencing, ChIP-seq. This Chapter will demonstrate that 
alterations in the SRI domain of SETD2 do not alter H3K36me3 placement. 
1.10 Thesis Contributions 
 The work described in this thesis would not have been possible without the work of many 
collaborators. The project described in Chapter 2 was a collaboration between the labs of Ian Davis, Kim 
Rathmell and Brian Strahl. The work on structure and sequence comparisons was completed by myself 
and Dr. Kathryn Hacker. Dr. Jordan Shavit and Andy Vo generated TALEN constructs. Dr. Hacker 
completed the experiments on protein stability and H3K36me3 levels. Dr. Stephen Shinsky generated data 
on the SET domain mutation. Julia DiFiore completed the experiments exploring protein function in yeast 
Set2. Dr. Yun-Chen ‘Jeanne’ Chiang completed the experiments on DNA damage, while I examined the 
effect of transcription inhibition in SETD2Δ cells. The results described in Chapter 3 were obtained in 
SETD2Δ cells generated by Dr. Hacker. The ChIP-seq was conducted in cells stably expressing constructs 
generated by Dr. Chiang. The High Throughput Sequencing Facility, J. Roach, and UNC Research 
Computing generated and initially processed sequencing data. All sequencing data was run through the 
data analysis pipeline generated by Austin Hepperla. 
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CHAPTER 2: Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a 
Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and 
Histone H3 Lys-36 Trimethylation2 
2.1 Introduction
Cancer is increasingly characterized by alterations in chromatin-modifying enzymes [18]. SETD2, 
a non-redundant histone H3 lysine 36 (H3K36) methyltransferase [1], has been found to be mutated in a 
growing list of tumor types, most notably in clear cell renal cell carcinoma (ccRCC) [13,18,110], but also in 
high-grade gliomas [22], breast cancer [107], bladder cancer [27] and acute lymphoblastic leukemia (ALL) 
[25,26,48]. Recent studies exploring intratumor heterogeneity in ccRCC identified distinct mutations in 
SETD2 from spatially distinct subsections of an individual tumor, suggesting that mutation of SETD2 is a 
critical and selected event in ccRCC cancer progression [20]. Mutations in SETD2 are predominantly 
inactivating, such as early nonsense or frameshift mutations, which lead to non-functional protein and global 
loss of H3K36me3 [13,17,20]. Missense mutations tend to cluster in two domains [6,13,17,18]: the SET 
domain, which catalyzes H3K36 trimethylation (H3K36me3) [3], and the SRI domain, which mediates the 
interaction between SETD2 and the hyperphosphorylated form of RNA Polymerase II (RNAPII) [6]. 
SETD2, and its yeast counterpart, Set2, both associate with RNAPII in a co-transcriptional manner 
[6,73,111].  In yeast, Set2 mediates all H3K36 methylation states (H3K36me1/me2/me3)  [67] and regulates 
the recruitment of chromatin-remodeling enzymes (Isw1b) and a histone deacetylase (Rpd3) [68] that 
functions to keep gene bodies deacetylated, thereby maintaining a more compact chromatin structure 
[112,113] that is more resistant to inappropriate and bi-directional transcription [65,68].  The Set2/SETD2 
pathway is also important for DNA repair [74,83,84,86,87,114] in both yeast and humans, as well as for 
proper mRNA splicing [17,71,115].  Although yeast Set2 can mediate all forms of H3K36 methylation, 
                                                     
2This research was originally published in the Journal of Biochemistry. Kathryn E. Hacker, Catherine C. 
Fahey, Stephen A. Shinsky, Yun-Chen J. Chiang, Julia V. DiFiore, Deepak Kumar Jha, Andy H. Vo, Jordan 
A. Shavit, Ian J. Davis, Brian D. Strahl, and W. Kimryn Rathmell. Structure/Function Analysis of Recurrent 
Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in 
Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. Journal of Biological Chemistry. 2016; 
40:21283-21295. © the American Society for Biochemistry and Molecular Biology.  
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SETD2 only trimethylates H3K36 [6]. Other methyltransferses (e.g., NSD2 and ASH1L) mediate mono- and 
dimethylation [3], indicating an increased complexity of H3K36 regulation in higher eukaryotes. Consistent 
with a more diverse role, H3K36me3 recruits a variety of effector proteins in addition to those that are 
recruited in yeast, including DNMT3b, which regulates gene body methylation [91], LEDGF, which functions 
in DNA repair [77], and ZMYND11, which regulates co-transcriptional splicing and transcription elongation 
[78,116].   
 The structural and functional similarities between SETD2 and Set2 provide an exceptional 
opportunity in which existing assays in S. cerevisiae can be applied to investigate the functional 
consequences of SETD2 mutations reported in human cancer.  In this work, we characterized cancer-
associated SETD2 mutations that occur at evolutionarily conserved residues in functionally important 
domains (i.e., the SET and SRI domains). We discovered that a missense mutation in the SET domain of 
SETD2 (R1625C) altered the capacity of this mutant to engage H3, leading to reduced protein stability, and 
a complete loss of H3K36me3.  Strikingly, the same mutation in yeast Set2 (R195C) resulted in an identical 
effect on H3K36me3, but not H3K36me1 or H3K36me2 levels (or biological outcomes associated with these 
lower methylation states). Further biological studies in human cells revealed that loss of H3K36me3 in the 
R1625C mutant leads to DNA repair defects, thereby revealing a greater understanding of how this 
recurrent mutation likely leads to a loss of SETD2 tumor suppressive activity.   
2.2 Results 
2.2.1 SETD2 and Set2 share a high degree of structural and sequence homology at their SET and 
SRI domains 
SETD2 and Set2 share significant structural and functional homology. SETD2 demonstrates strong 
sequence conservation at all of the annotated functional domains present in yeast Set2: AWS (associated 
with SET) 42%, SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) 56%, PS (Post SET) 59%, coiled-coil 33%, 
WW 26%, and SRI (Set2 Rpb1 Interacting) 35% (Figure 2.1A). Given this similarity, we compared the 
structure of the SETD2 and Set2 SET domains to identify highly conserved residues for further study. The 
structure of the SET domain in SETD2 has been solved by crystallography [117] whereas the SET domain 
of Set2 was predicted here using I-TASSER [118–121].  When the predicted structure of the Set2 SET 
domain was aligned with the crystal structure of the SETD2 SET domain, the structures were strikingly 
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similar (Figure 2.1B).  We then examined the conservation of amino acids previously reported to be mutated 
in human ccRCC [13,17,18,20] across six organisms (H. sapiens, D. melanogaster, S. cerevisiae, M. 
musculus, X. tropicalis, and D. rerio). Seven of the nine ccRCC mutations occur at residues that are 
conserved across all model organisms (Figure 2.1C). Additionally, three of these seven mutations occur in 
a region previously identified to act as the catalytic site for lysine methylation [6]. One of these mutations, 
Figure 2.1: SETD2 and yeast Set2 show high sequence and structural conservation. A) Comparison of 
SETD2 and yeast Set2 (ySet2) annotated protein structure. Percentage of conserved residues within the 
BLAST aligned domain sequence is indicated. Annotated domains include: AWS: Associated with SET, 
SET: Su(var)3-9, Enhancer-of-zeste, Trithorax, PS: Post-SET, CC: Coiled-Coil, LCR: Low Charge 
Region, WW: conserved Trp residues, SRI: Set2 Rpb1 interacting. Numbers represent percent 
conservation. B) Alignment of human SET domain crystal structure (blue) with I-TASSER protein structure 
prediction for yeast SET domain (yellow). N-terminus is marked in green, C-terminus is marked in pink, 
and residues mutated are shown as sticks. C) Partial SET domain sequence alignment across multiple 
species. Amino acids 1612-1673 of human SET domain (amino acids 1550-1667) are shown. Residues 
mutated in ccRCC are in red and marked with an asterisk. The arrow indicates R1625, the residue 
mutated for study.  The black box indicates residues previously shown to be an important catalytic site. 
Residues that are conserved across species are indicated in green. D) SRI domain sequence alignment 
across multiple species. Residues mutated in ccRCC are in red and marked with an asterisk. The arrow 
indicates R2510, the residue mutated for study. Residues that are conserved across species are indicated 
in green. E) Alignment of human SRI domain crystal structure (blue) with yeast SRI domain crystal 
structure (yellow). N-terminus is marked in green, C-terminus is marked in pink, and residues mutated 
are shown as sticks. 
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R1625C, is found in a location that is adjacent to the S-  adenosylmethionine (SAM) binding site in the 
structure, and thus would be predicted to impact catalytic activity (Figure 2.1B).  This residue is the most 
common site of missense mutation  reported in both CBioPortal  [11,12] and COSMIC [122]. The specific 
arginine to cysteine mutation is found in both glioma [22] and ccRCC [18]. Significantly, mutation of the 
corresponding residue in S. cerevisiae is known to affect Set2 catalytic activity [123].  Given its location and 
mutation frequency, we chose this mutation for further analysis.   
We then examined sequence and structural conservation of the SRI domain and location of ccRCC-
associated missense mutations. In contrast to the SET domain, primary sequence of the SRI domain is 
less conserved across model organisms (Figure 2.1D). However, the aligned crystal structures of yeast 
[124] and human [5] SRI domains display structural conservation (Figure 2.1E). In particular, the predicted 
site of SETD2 and RNAPII interaction was previously suggested to be the concave surface between alpha 
helix 1 (1) and alpha helix 2 (2) [5]. The physical relationship of these helices appears conserved between 
Set2 and SETD2. We therefore selected the R2510 residue for further study, as this amino acid is 
recurrently mutated (R2510H, R2510L) in ccRCC [17,18] and is predicted to be important for SETD2-
RNAPII interaction by in vitro peptide interaction assays [5]. 
2.2.2 SET domain mutation destabilizes SETD2 in cells  
To establish a human cell system in which to study the function of SETD2 mutants, we generated 
SETD2 deficient cells (SETD2Δ). TAL effector nucleases (TALEN) (45, 46) targeting exon 3 of SETD2 were 
introduced into two immortalized kidney cell lines (human SV-40 immortalized proximal tubule kidney cells 
(HKC)(47) and 293T).  Individual clones of TALEN-treated cells were isolated and loss of H3K36me3 was 
demonstrated by immunocytochemistry (Figure 2.2A). We verified inactivation of both alleles of SETD2 via 
Sanger sequencing. Representative allelic sequencing is shown (Figure 2.2B). 
We then exogenously expressed a truncated wild-type FLAG-tagged form of SETD2 (amino acids 
1323-2564; tSETD2), which includes all known functional domains. The R1625C or R2510H mutants were 
generated in tSETD2. Relative to tSETD2 and R2510H, R1625C protein levels were reduced (Figure 2.2C). 
R1625C mutant mRNA levels were also less abundant (Figure 2.2D). We examined protein stability after 
treatment with the protein synthesis inhibitor cycloheximide. The R1625C protein demonstrated a 
significantly shorter half-life compared to that of wild-type (Figure 2.2E). In contrast, the half-life of the 
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R2510H mutant was unchanged (Figure 2.2E).  These data suggest that the decreased protein level of the 
R1625C SET domain mutant results from both decreased RNA and a shortened protein half-life.  
2.2.3 Histone H3 lysine 36 trimethylation is linked to SETD2 mutational status  
We interrogated H3K36 methylation status in cells transiently transfected with either tSETD2 or the 
mutants, R1625C and R2510H. Using immunocytochemistry (ICC) we found that transfection of tSETD2 
resulted in global restoration of H3K36me3 (Figure 2.2F), demonstrating that the N-terminus is not required 
Figure 2.2: ccRCC specific mutations in SETD2 have separate effects on H3K36me3.  A) 
Immunocytochemistry of HKC SETD2 wild-type (top) and SETD2Δ cells for H3K36me3. B) Sanger 
sequencing results of TALEN target sequence in exon 3 of SETD2. Two allelic variants in one HKC SETD2Δ 
clone are represented. C)  Immunoblot displaying protein expression level 72 hours after transfection in 
293T cells. Ku80 acts as a loading control. D) Average quantification SETD2/Ku80 over the hours of 12 
hours following cycloheximide treatment in three independent western blots (left). Average half-life of 
mutant SETD2 proteins (right). E) Average RNA levels of tSETD2, R1625C, or R2510H, as determined by 
qPCR for tSETD2 levels. F) Anti-H3K36me3 immunocytochemistry on HKC cells at 72 hours post-
transfection following reintroduction of GFP, wild-type tSETD2, R1625C, or R2510H. G)  Anti-H3K36 
methylation immunoblot displaying levels of methylation levels at 72 hours post-transfection following 
reintroduction of GFP, wild-type tSETD2, R1625C or R2510H. Quantification of H3K36me3/H3 levels is 
shown beneath blot. H) ChIP-qPCR displaying H3K36me3 levels at exonic locations in Myc (left) and CDK2 
(right), displayed as ChIP signal/Input.  Error bars represent standard error. Significance comparisons were 
made to SETD2 inactive + GFP. 
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for catalytic activity of SETD2. Transfection of R1625C (SET domain) mutant construct failed to restore 
H3K36me3. In contrast, expression of the R2510H SRI mutant globally restored H3K36me3.  
We next examined the H3K36 methylation status by western blot analysis. Consistent with findings 
from ICC, SETD2Δ cells show complete loss of H3K36me3. Trimethylation was restored to wild-type levels 
by expression of either the tSETD2 or the SRI mutant. In contrast, the SET domain mutant failed to 
trimethylate H3K36 (Figure 2.2G). Monomethylation (H3K36me1) and dimethylation (H3K36me2) were 
unaffected by SETD2 loss or expression of SETD2 variants (Figure 2.2G). These results are in agreement 
with the findings that SETD2 is the exclusive H3K36 trimethyltransferase in mammalian cells. 
We then asked whether expression of either tSETD2 or R2510H restored H3K36me3 to levels 
similar to wild-type cells at specific loci. H3K36me3 levels have been shown to increase along the gene 
body with preference for exons [70]. Using ChIP-qPCR, we examined the H3K36me3 levels at multiple 
exons of two genes, CDK2 and MYC, which had previously been described [81]. As expected, SETD2Δ 
cells displayed low H3K36me3 levels at all sites. (Figure 2.2H). Expression of tSETD2 recapitulated the 
previously described pattern for H3K36me3 in wild-type cells [81] at both CDK2 and MYC, with higher signal 
at exons 5 and 6 relative to exon 1 in CDK2, and in exons 2 and 3 relative to exon 1 in MYC. Cells 
expressing the R1625C SET domain mutant displayed loss of H3K36me3 at levels similar to that of 
SETD2Δ cells. Finally, expression of the R2510H mutant also showed greater signal at later exons, 
indicating that this point mutation restores not only the levels of methylation, but the spatial placement of 
these methyl marks on actively transcribed genes.  
2.2.4 The SETD2 R1625C variant is enzymatically inactive in vitro and has diminished substrate 
binding 
Given the R1625C SETD2 variant is associated with loss of H3K36me3 in cells, we asked whether 
the R1625C mutation disrupts the methyltransferase activity of SETD2 in vitro. To do this, we expressed 
and purified from bacteria a wild-type or R1625C mutated fragment of SETD2 (residues 1345-1711) 
containing the SET domain. Both the wild-type and the R1625C SET domain constructs yielded soluble 
proteins that were >90% pure as assessed by SDS-PAGE (Figure 2.3A). Methyltransferase activity was 
then assessed using a radiometric assay with chicken oligo-nucleosomes as the substrate. Whereas wild-
type SETD2 displayed robust activity, the R1625C variant displayed little enzymatic activity over the no 
enzyme control (Figure 2.3B). 
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Figure 2.3: The SETD2 R1625C variant is catalytically inactive and has reduced substrate-binding capacity. 
A) Coomassie Blue stained SDS-PAGE gel of 1μg of purified wild type or R1625C variant SETD2 construct 
containing amino acids 1345-1711 (42kDa). Precision Plus Protein standards (BioRad) are annotated.  B) 
Radiometric histone methyltransferaes assays comparing the catalytic activity of the wild type and R1625C 
variant when chicken olido-nucleosomes were the substrate. The amount of 3H-methyl incorporated is 
quantified as counts per minute (CPM) and error bars represent the standard error of the mean (n=3). A 
reaction without enzyme served as a negative control. C) Circular Diochroism (CD) absorbance spectra 
(plotted as the molar ellipticity ([Θ]) as a function of wavelength) comparing the secondary structure of wild 
type SETD2 (black) and the R1625C variant (purple). D) Thermal melt curves showing the change in CD 
absorbance at 207nm over the temperature range from 20-95°C for wild type SETD2 (black) and the 
R1625C variant (purple). E) Structural analysis of R1625. The crystal structure of the SETD2 SET domain 
(show in tan) bound to S-adenosyl-L-homocystein (SAH, shown in green) near the active site. Hydrogen 
bonds  are shown as gray dashed lines (PDB code 4H12). F) In silico mutagenesis analysis (performed in 
PyMOL, Schrodinger Inc.)). The distances between the R1625C thiol and the carbonyl oxygens of A1617 
and T1618 were measured in PyMOL (yellow dashed lines). G) Peptide pull-down assays comparing the 
binding of the wild type and the R1625C variant to the indicated histone H3 peptides. All peptides were 
biotinylated at the C-terminus and were unmodified, or modified as indicated. Streptavidin coated magnetic 
beads without peptide served as the negative control. Short (top) and Long (bottom) refer to exposure 
length.   
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We next sought to determine why the R1625C variant is catalytically inactive. We first considered 
whether this mutation results in a misfolded protein, thereby inactivating the SET domain. We compared 
the circular dichroism (CD) spectra of the wild-type SETD2 with the R1625C variant. The CD spectra in the 
low UV range (185-260nm) of the wild-type and the R1625C variant were nearly indistinguishable, 
suggesting that the R1625C substitution does not alter the secondary structure of the SET domain (Figure 
2.3C). To determine if the R1625C variant alters the thermal stability of the SET domain, we monitored the 
CD signal at the 207 nm peak over a temperature range from 20-95°C. Both the wild-type and the R1625C 
variant showed highly similar thermal melt curves with a melting temperature (Tm) of approximately 55°C 
(Figure 2.3D). Together, these results suggest that the loss of catalytic activity observed for the R1625C 
variant is not due to protein misfolding or reduced thermal stability.  
Structural analysis of the SETD2 SET domain shows that R1625 is positioned within the active site, 
opposite the SAM binding pocket, and is located about 7Å away from the sulfur group of S-adenosyl-
homocysteine (SAH) (Figure 2.3E). While substitution of R1625 with cysteine would not be expected to 
directly disrupt SAM binding, the R1625 side chain engages in three hydrogen bonds with the backbone 
carbonyl oxygens of A1617 and T1618 (Figure 2.3E). Substituting cysteine for R1625 using in silico 
mutagenesis showed that every possibly cysteine rotamer would cause steric clashes. The cysteine side 
chain would not recapitulate the hydrogen bonding network of R1625 when oriented in the same direction 
as the R1625 side chain observed in the crystal structure (Figure 2.3F). Although no structure of the SETD2 
SET domain ternary complex containing histone H3 is available, the location of R1625 in close proximity 
to, but opposite the SAM binding pocket suggests that R1625 may directly or indirectly engage H3 or may 
maintain local structural integrity that aids substrate binding.  
To determine if the R1625C variant has altered substrate binding, we performed peptide pull-down 
experiments using histone H3 peptides that were unmodified, or methylated at K36. The pull-down 
experiments showed that the R1625C variant associated with all of the histone peptides to a lesser degree 
compared to the wild-type SETD2 SET domain, suggesting that the R1625C substitution weakens substrate 
binding (Figure 2.3G). Taken together, our results suggest that the R1625C substitution impairs enzymatic 
activity by reducing substrate binding, which is likely a consequence of fine structural disturbances induced 
by loss of the R1625 hydrogen bonding network within the active site.  
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2.2.5 Domain-specific mutations in yeast Set2 separate roles of H3K36 methylation states  
To further explore the functional significance of ccRCC-associated mutations, we took advantage 
of several well-characterized phenotypic assays in S. cerevisiae. Using set2Δ cells, which are devoid of all 
H3K36 methylation [123], we created strains that either contained vector alone, or strains that exogenously 
express either wild-type or mutated forms of Set2.  Mutant forms of Set2 included the homologous SETD2 
SET domain mutant (R195C), the homologous SETD2 SRI mutant (K663L), or a control SET domain 
mutant (H199L) previously characterized to disrupt both tri- and di- methylation, while retaining 
monomethylation activity [123].  As expected, Set2 loss resulted in the complete absence of mono-, di-, 
and trimethylation of H3K36, which was rescued upon addition of wild-type SET2 (Figure 2.4A).  As 
previously shown, the H199L mutant only restored monomethylation.  In contrast, while the K663L mutant 
restored all H3K36 methylation states, the R195C only restored H3K36 mono- and dimethylation.  
Intriguingly, the restoration of H3K36 mono- and dimethylation by the R195C mutant mimics the status of 
SETD2 deficient human cells (i.e., both have a selective loss of H3K36me3). Since the SETD2 R1625C 
mutant demonstrated decreased protein stability in human cells, we examined protein levels of the R195C 
mutant in the yeast cells. Following cycloheximide treatment we observed decreased protein levels of the 
R195C mutant relative to wild-type Set2, particularly at 3 hours post-treatment. This effect was rescued by 
treatment with the proteosome inhibitor MG132 (Figure 2.4B). This suggests that, like in humans, the 
R195C variant is less stable than wildtype in yeast cells. Loss of Set2 has been implicated in various 
phenotypes in S. cerevisiae, including transcription elongation defects, cryptic initiation and sensitivity to 
DNA damaging agents [123]. We asked whether the R195C Set2 mutant would be associated with any of 
these phenotypes. To examine transcriptional elongation, we performed a spotting assay in the presence 
of the transcription elongation inhibitor 6-Azauracil (6-AU). This assay has been previously used to assay 
for the presence of transcriptional elongation defects in yeast [111].  As expected, wild-type yeast were 
sensitive to 6-AU (200 µg/mL), whereas set2Δ cells were resistant to this drug (Figure 2.4C) [111]. While 
expression of wild-type SET2 restored sensitivity to 6-AU, the H199L mutant did not.  The R195C and 
K663L mutants behaved similar to wild-type Set2. These data suggest that H3K36me2 is primarily 
responsible for the sensitivity to inhibitors of transcriptional elongation.  
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Cryptic initiation has been previously associated with Set2 loss [68]. We therefore assessed the 
effects of our Set2 mutations in a cryptic transcription reporter assay.  This assay monitors the growth of 
yeast cells that contain the HIS3 gene with a cryptic start-site that exists in the FLO8 gene. Importantly, the 
cryptic start site is out of frame when the 5’ promoter is used and a functional transcript is only produced if 
the 3’ cryptic start site is utilized. In this setting, cryptic transcription results in expression of HIS3, which 
can restore growth in medium lacking histidine.  Consistent with previous results [68], loss of Set2 permits 
growth in the absence of histidine (Figure 2.4D). No growth was observed in the cells expressing the R195C 
or K663L mutants. However, cell growth occurred in the presence of the H199L mutant (Figure 2.4D). These 
Figure 2.4: Modeling of ccRCC specific mutations in Set2 results in separate effects based on H3K36me 
status. A) Anti-H3K36me immunoblots displaying levels of methylation in set2Δ yeast cells, as well as yeast 
with the indicated Set2 mutation. Quantification of H3K36me3/H3 is shown as a bar graph. B) Western 
results for Set2 and R195C protein levels after treatment with cyclohexamide (100µg/mL) and MG132 
(75µM). C) 6-Azauracil (6-AU) treatment of wild-type or set2∆ yeast cells expressing the indicated Set2 
mutations. D) Phleomycin treatment of wild-type or set2∆ yeast cells expressing the indicated Set2 
mutations. E) Cryptic initiation assay of wild-type or set2∆ yeast cells expressing the indicated Set2 
mutations. F) Table summary of yeast phenotypes for each of the Set2 mutants 
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data indicate that trimethylation is dispensable for preventing cryptic initiation, whereas dimethylation is 
required to suppress this phenotype. 
Recent studies have demonstrated that yeast lacking Set2 cannot properly activate the DNA-
damage checkpoint [123,125].  To determine if the RCC-associated SET domain mutation impacts this 
phenotype, we assessed the impact of the Set2 point mutants on growth in the presence of phleomycin, a 
double-strand break-inducing agent. As expected, set2Δ cells displayed increased sensitivity to phleomycin 
relative to Set2 wild-type yeast (Figure 2.4E). set2Δ cells expressing either wild-type Set2 or the R195C or 
K663L mutants showed similar sensitivity as the wild-type rescue. However, yeast expressing the H199L 
mutant showed a similar level of sensitivity as the set2Δ cells (Figure 2.4E). Taken together, these data 
indicate that the cellular phenotypes associated with Set2 loss in yeast are associated with H3K36me2, 
and that H3K36me3 is dispensable for these activities (summarized in Figure 2.4F).  
2.2.6 Human kidney cells display an H3K36 trimethylation-dependent DNA damage response  
Because of the exclusivity of SETD2 in mediating trimethlyation in human cells, we studied similar 
phenotypes to those examined in yeast in human cells that express ccRCC-relevant mutants. We first 
examined the effect of the transcriptional elongation inhibitor 5,6-Dichlorobenzimidazole 1-β-D-
ribofuranoside (DRB) on cell survival. DRB inhibits CDK9, which results in premature termination of 
transcription [126]. Assessing viability at 12 hour time points for 3 days, we observed that DRB-associated 
toxicity did not differ between SETD2 wild-type and SETD2Δ cells (Figure 2.5A).  
Several recent studies have examined the effect of SETD2 loss in human cells on the response to 
DNA damage [74,83,84,86,87]. To further explore the role of H3K36me3 in the DNA damage response, we 
irradiated HKC cells to 2 gray and then performed immunofluorescence for γH2A.X, a marker of DNA 
damage. At 30 minutes post irradiation, γH2A.X foci were seen in all cell types at similar levels (Figure 5B). 
In untransfected and in control transfected wild-type cells, the number of foci greatly decreased by 1 hour 
and largely resolved by 4 hours. However, in SETD2∆ cells, the number of γH2A.X foci remained elevated 
at both 1 hour and 4 hours. Expression of tSETD2 in SETD2Δ cells led to resolution of foci at time points 
similar to wild-type cells. Cells expressing the SRI mutant, R2510H, also showed rapid foci resolution. 
However, foci persisted in cells expressing the R1625C mutant (Figure 2.5B). Quantification of these results  
  
25 
 
  
Figure 2.5: Caption on following page.  
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demonstrated that both SETD2Δ cells and R1625C expressing cells had a significantly higher percentage 
of cells with greater than 10 foci compared with the other conditions (Figure 2.5C).  
We quantified γH2A.X by immunoblotting, enabling us to account for changes in total protein and 
histone levels. These studies were performed in 293T cells, as additional validation of results in HKC cells. 
As observed with HKC cells, regardless of SETD2 status, 293T cells showed increased total γH2A.X at 30 
minutes post irradiation (Figure 2.5D). By 4 hours γH2A.X levels returned to baseline in cells with H3K36 
trimethylation (WT, tSETD2, R2510H). However, elevated levels of γH2A.X were observed in cells lacking 
H3K36me3 associated with SETD2 loss or R1625C expression. Finally, we examined the effect of 
irradiation on viability using a colony formation assay. The fraction of surviving colonies did not differ 
between SETD2 wild-type and SETD2Δ cells (Figure 2.5E). Overall, these findings demonstrate that 
SETD2-mediated H3K36me3 is coupled to the efficient resolution of double-strand breaks. Corresponding 
to results in yeast, loss of trimethylation is not associated with enhanced sensitivity due to inhibition of 
transcriptional elongation or from DNA damage. 
  
Figure 2.5 H3K36me3 loss delays γH2AX foci resolution after DNA damage but does not alter viability. A) 
Surviving fraction of cells at 12, 24, 36, 48, and 72 hours post treatment with 100 µM 5,6-
Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB). Fraction was determined compared to an untreated 
control. Error bars represent standard deviation of triplicate treatments. B)  γH2AX foci formation at 0, 0.5, 
1 and 4 hours after irradiation (2Gy) in HKC wild-type or SETD2-inactivated cells transfected with GFP, 
tSETD2, R1625C mutant or R2510H mutant. The nuclei were visualized by DAPI staining. Representative 
immunofluorescence images are shown; scale bar at 10 μm. At least 5 fields were taken from each condition 
and four independent experiments were performed. C) Percentage of HKC cells with more than 10 γH2AX 
foci per cell at 0, 0.5, 1, and 4 hours after irradiation (2Gy). Error bars represent standard error. *p<0.05, 
**p<0.01, (two-sided t-test, comparison to HKC wild-type). D) Immunoblot analysis for the expression of 
γH2AX and H3 (loading control) from the 293 wild-type or SETD2-inactivated cells transfected with GFP, 
tSETD2, SET domain R1625C mutant or SRI domain R2510H mutant. The cells were irradiated by 2 Gy, 
and histones were acid-extracted at various time points. Average quantification of γH2AX/H3 after 
irradiation in three independent western blots Error bars represent standard error. *p<0.05, **p<0.01, 
***p<0.001 (two-sided t-test, comparison to 293 wild-type + GFP). E) Radiation foci formation assay. 
Surviving fraction represents ratio of treatment (37, 75, 150, 300 rads) to 0 rad comparison. Error bars 
represent standard deviation of triplicate results. 
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2.3 Discussion 
In an effort to explore the function of missense mutations identified in human cancers, we examined 
several recurrent mutations that occur at evolutionarily conserved residues in yeast and human cell lines.  
The striking homology between SETD2 and Set2 creates an opportunity to compare the effects of mutations 
while taking advantage of the strengths of each model system.  Indeed, a recent study [127] also modeled 
cancer mutations in yeast, highlighting the utility and power of yeast to be a robust model system to aid in 
human protein analyses.  In this paper, we investigated how two highly conserved SETD2 residues that are 
commonly mutated in cancer affect the functions of this enzyme. Limited studies have explored the potential 
roles that SETD2 loss may play in cancer development. We found that mutation of the SET domain, but not 
the SRI domain, resulted in effects in the human and yeast assays.  Specifically, we identified R1625C as 
a critical mutation that impacted SETD2 enzymatic activity and protein stability in cells –an effect also noted 
when this mutation was modeled in yeast Set2.   Loss of H3K36me3 in human cells also led to defects in 
DNA repair, indicating a potential mechanism by which SETD2 functions as a tumor suppressor. To our 
knowledge, this study is the first to dissect the impact of cancer-associated mutations in SETD2, and further 
validate using yeast as a model to complement human cell analyses.  
A key discovery emerged from the study of the R1625C mutant. In contrast to the human R1625C 
variant which was catalytically inactive in vitro, the homologous substitution in yeast Set2 led to an 
uncoupling of di- and trimethylating activities. This suggests that this residue may be important for the 
specific trimethylating activity of the enzyme. Moreover, many substrate binding interactions govern 
stability. Thus, the reduced protein stability (in the absence of other thermal instability) may reflect a 
structural role that differentiates mono-, di-, and trimethylating activity. Because of this unique mode of 
regulation, the R195C mutation allowed us to examine the functions specifically associated with the 
trimethylated state of H3K36 in cells (i.e., impaired transcriptional elongation, cryptic initiation, and impaired 
survival in the face of DNA damage).  Consistent with other reports that examined cryptic initiation 
[112,128], we found that H3K36me3 is dispensable whereas H3K36me1/me2 is required to suppress 
cryptic initiation, as well as for transcription elongation and DNA damage survival phenotypes.  In contrast, 
the SET domain mutation in SETD2 had a similar impact on H3K36me3 levels but resulted in a clear DNA 
damage response phenotype.  
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These studies offer a rationale for differences in observed phenotypes in SETD2 deficient human 
cells associated with Set2 loss in yeast, including cryptic initiation and impaired transcriptional elongation. 
However, impaired response to DNA damage, as we observed, has been reported for both mammalian 
systems and Set2 in yeast, linking this feature with H3K36 trimethylation.  The yH2A.X results suggest that 
resolution of DNA strand breaks in human cells requires H3K36me3. Due to the presence of multiple H3K36 
dimethylating enzymes in mammalian cells, absence of H3K36me2 is rarely encountered in human models. 
H3K36me2 is induced by ionizing radiation and improves association of early DNA repair components with 
an induced break, and improved repair by non-homologous end joining (NHEJ) in human cells [114]. 
Although our data show that the resolution of strand breaks, as measured by clearance of γH2A.X foci, was 
delayed in the absence of H3K36me3, our data also shows that H3K36me3 loss does not affect viability 
after radiation in mammalian cells. Thus, loss of dimethylation may convey a sensitivity to DNA damage 
that is not present in the absence of SETD2 trimethylating activity. It is important to consider that multiple 
factors may influence cell death in transformed cells. However, these distinct findings in yeast and 
mammalian systems indicate a complex level of regulation of DNA repair mediated by the histone code at 
H3 lysine 36. Multiple studies have concluded that the loss of SETD2 confers a variety of types of genomic 
instability, ranging from microsatellite instability to impairment of NHEJ [89,90,125]. Our data agree with 
these results. 
Through modeling disease-relevant SETD2 mutations, we were able to gain insight into H3K36me3 
function and dissect the roles of H3K36 dimethylation and trimethylation. Future studies will further explore 
the roles of the SETD2 SRI domain and examine the effects of additional mutations, and will further define 
the role of SETD2 loss in the development of kidney cancer and other tumor types. 
2.4 Methods 
2.4.1 Modeling SETD2 and Set2 
The primary protein sequences of Set2 from Saccharomyces cerevisiae and SETD2 from Homo 
sapiens were compared via BLAST alignment analysis and the percentage of homology between annotated 
domains was determined using the percentage overlap of the BLAST-aligned regions.  The primary 
sequences of the SET and SRI domains of the enzyme responsible for H3K36 methylation from H. sapiens, 
S. cerevisiae, X. tropicalis, D. melanogaster, D. rerio, and M. musculus were aligned using ClustalOmega 
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[129], and annotated with reported SETD2 mutations in ccRCC [13,17,18,20]. The structure of the SETD2 
SET domain [117], SETD2 SRI domain [5] and Set2 SRI domain [124] have been previously reported. To 
predict the structure of the yeast SET domain, the amino acid sequence (UniProtKB, P46995) was 
submitted to I-TASSER using the default parameters [118–121]. The ribbon structures were aligned using 
the align command in the PyMOL Molecular Graphics System [130].  
2.4.2 Mammalian Cell Lines Transfections and Phenotypic Assays 
293T human embryonic kidney cells were generously provided by Dr. Jenny Ting, Chapel Hill, NC. 
The SV-40 transformed human renal tubule epithelial cell line (referred to as HKC) was obtained from Dr. 
Lorraine Racusen, Baltimore, MD [131]. A pair of vectors containing TAL effector nucleases (TALENs) 
targeting exon 3 of SETD2 was generated using the REAL (Restriction Enzyme And Ligation) assembly 
method. Component plasmids were obtained from Addgene (www.addgene.org/talengineering/talenkit/).  
Briefly, target sites were selected and TALENs designed using Zifit (http://zifit.partners.org/ZiFiT/), followed 
by assembly [132]. The TALEN target sequences are: 5'-TCATGTAACATCCAGGCC -3' and 5'-
ACAGCAGTAGCATCTCCA-3'.   
An expression construct containing a N-terminal truncated form of SETD2 (amino acids 1323 to 
2564; tSETD2) was sequence-optimized for expression in human cells, tagged with the FLAG sequence 
on the C-terminus, and synthesized by Life Technologies. tSETD2 was specifically used as it models the 
yeast protein in domain structure, and expression of full-length SETD2 was technically unfeasible. tSETD2 
was subcloned into the pINDUCER20 vector [133]. Disease-relevant SETD2 mutations were introduced 
into the tSETD2 pINDUCER20 construct using the QuikChange II Site-Directed Mutagenesis Kit according 
to the manufacturer’s instructions (Agilent Technologies).   Mutations were verified through direct DNA 
sequence analysis. 
293T and HKC human renal cells were transfected with the TALEN constructs, tSETD2 construct, 
and mutation constructs using Amaxa® cell Line Nucleofector® Kit V (Lonza). For the protein stability 
assay, cycloheximide (100 ng/mL) was applied to cells 72 hours post-transfection.  For the 5,6-
Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) transcription inhibition assay, 1000 cells/well were 
plated in triplicate on a 96 well plate and treated with 100uM DRB for 72 hours, with viability being measured 
every 12 hours by Cell Titer Glo (Promega). 
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2.4.3 Sequencing and allelic analysis 
DNA was extracted and the SETD2 TALEN target site was PCR-amplified (primers: 5'-
ACAGGGACGACAGAAGGTGTCATT-3' and 5'-ACTGGTGCTGGTGATGAGAGTGTT-3'), sequenced 
(Applied Biosystems 3730xl Genetic Analyzers, Life Technologies) and analyzed (Sequencher DNA 
analysis software version 5.0, Gene Codes Corporation). Allelic analysis was performed by subcloning 
individual PCR products (TOPO TA Cloning® Kit, 45-0641, Life Technologies). DNA from individual clones 
was PCR amplified, sequenced and analyzed as described above. 
2.4.4 Immunoblot analysis 
To isolate mammalian cellular proteins, cells were lysed in Mammalian Protein Extraction Reagent 
(M-PER; Pierce Biotechnology) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche).  
Histones were extracted using an overnight acid extraction protocol (Abcam). For yeast immunoblots, 
asynchronously grown mid-log (0.6-0.8 OD) phase cultures were lysed by SUMEB using glass beads 
methods described by the Gottschling Lab: http://labs.fhcrc.org/gottschling/Yeast%20Protocols/pprep.html. 
2.4.5 Antibodies 
Antibodies used include: SETD2 (HPA042451, Sigma-Aldrich, St. Louis, MO), Ku80 (ab3107, 
Abcam), H3K36me3 (ab9050, Abcam), total H3 (Abcam, ab10799; Epicypher, 13-0001), H3K36me2 
(39255, Active Motif), H3K36me1 (ab9048, Abcam), γH2AX (ab2893; Abcam), GST (EpiCypher # 13-0022), 
and Set2 (raised in Strahl lab). Secondary antibodies used in human studies were anti-mouse and anti-
rabbit IRDye Secondary Antibodies from LI-COR Biosciences (Lincoln, NE). HRP-conjugated donkey anti-
Rabbit secondary antibody was used (Amersham) for yeast studies. Human antibodies were detected using 
the Odyssey IR imager (LICOR Biosciences) and densitometry analysis was performed using ImageStudio 
Ver2.0. The yeast immunoblots were developed using ECL-Prime (Amersham) and densitrometry analysis 
was done using ImageJ (NIH). 
2.4.6 Immunocytochemistry 
Cells were fixed with 4% para-formaldehyde for 15 minutes and permeabilized using 0.25% Triton 
X-100 in PBS. Endogenous peroxidase activity was blocked by incubation in 1% H2O2. Cells were then 
blocked in 5% bovine serum albumin followed by incubation in primary antibody. The Vectastain ABC Kit 
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(PK6101, Vector Laboratories) was used for secondary antibody and HRP conjugation followed by the DAB 
peroxidase substrate kit (SK-3100, Vector Laboratories) and hematoxylin staining.  
2.4.7 Chromatin Immunoprecipitation  
Cells were fixed in 1% formaldehyde for 10 minutes, quenched with 125 mM glycine treatment, and 
homogenized in hypotonic solution (10 mM Tris pH 7.4; 15mM NaCl; 60mM KCl; 1mM EDTA; 0.1% NP-40; 
5% sucrose; 1x protease inhibitors). Nuclei were separated by centrifugation through a sucrose pad (10mM 
Tris pH 7.4; 15mM NaCl; 60mM KCl; 10% sucrose; 1x protease inhibitors) then resuspended in ChIPs 
buffer (10mM Tris pH 7.4; 100mM NaCl; 60mM KCl; 1mM EDTA; 0.1% NP-40; 1x protease inhibitors, 0.05% 
SDS) and sonicated to obtain DNA between 200 bp to 1 kb.  DNA was immunoprecipitated with H3K36me3 
antibody prebound to protein A/G beads.  Immunoprecipitated complexes were washed, RNAse and 
Proteinase K treated, and protein-DNA cross-links were reversed by overnight incubation at 65°C.  
2.4.8 Quantitative RT-PCR  
Total RNA was extracted using the Qiagen RNeasy mini kit. cDNA was made from total RNA using 
random primers and Superscript II Reverse Transcriptase reagents (Invitrogen). Primers used for RT-PCR 
are listed in table 2.1. 
2.4.9 Expression and Purification of human SETD2 
An E. coli codon-optimized synthetic gene corresponding to human SETD2 (UniProtKB ID 
Q9BYW2) residues 1345-1711 followed by a stop codon was cloned into the pGEX-6P-2 expression vector 
(GE Healthcare) using standard procedures. The protein was expressed in soluBL21 (DE3) (Amsbio) cells 
Target Forward Primer (5'-3') Reverse Primer (5'-3') 
tSETD2 CACCATGACACAGGGCCA GGGTGTCCTTGATGCTGTT 
c-Myc Exon 1 GCCGCATCCACGAAACTTT TCCTTGCTCGGGTGTTGTAAG 
c-Myc Exon 2 TGCCCCTCAACGTTAGCTTC GGCTGCACCGAGTCGTAGTC 
c-Myc Exon 3 CCTGAGCAATCACCTATGAACTTG CAAGGTTGTGAGGTTGCATTTG 
CDK2 Exon 1 GTCGGGAACTCGGTGGGAG AGAAGGCGGACCCTGGCTC 
CDK2 Exon 5 CATCTGGAGCCTGGGCTGCA TGGGGAGGAGAGGGAGGGGG 
CDK2 Exon 6 CCCTATTCCCTGGAGATTCTG CTCCGTCCATCTTCATCCAG 
Table 2.1: Primers used for real-time PCR in ChIP-PCR 
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by growing cells in Terrific Broth II media (MP Biomedicals) at 37°C until an 0D600 of ~0.6 then chilling the 
cells for 30 minutes at 4°C before inducing them with 1mM IPTG in the presence of 25 μM ZnCl2 for 20 
hours at 16°C. Cells were harvested by centrifugation and pellets were flash frozen in liquid nitrogen. For 
purification, thawed cell pellets were resuspended in binding buffer (50mM Tris pH 7.3, 300mM NaCl, 4mM 
dithiothreitol (DTT), 10% glycerol and 1 μM ZnCl2) supplemented with 1 Complete mini-EDTA-Free 
Protease Inhibitor Tablet (Roche), 0.1mM phenylmethane sulfonyl fluoride (PMSF), 0.5mg/mL chicken egg 
lysozyme, and 0.2 % (v/v) Triton X-100 and incubated on ice for 45 minutes, then lysed with sonication and 
clarified by centrifugation. Clarified lysates were diluted 1:2 with binding buffer and applied to a 5mL 
glutathione agarose gravity flow column (pre-equilibrated with 10 column volumes (CV) of binding buffer) 
at a flow rate ~ 0.5mL/min at 4°C. The bound protein was washed with 10CV of binding buffer then eluted 
from the column with 35 mLs of elution buffer (50mM Tris pH 8.0, 300mM NaCl, 4mM DTT, 10% glycerol, 
and 10mM reduced L-glutathione). The eluted protein was mixed with Precision Protease (GE Healthcare) 
and exhaustively dialyzed against binding buffer, without ZnCl2, over the course of 20 hours at 4°C. The 
cleaved protein sample was applied to a pre-equilibrated 5mL glutathione agarose gravity flow column at a 
flow rate ~ 0.5mL/min at 4°C and the flow-through was collected and concentrated using an Amicon-Ultra 
15 concentrator (Millipore). The Bradford Assay and and SDS-PAGE analysis were used to determine the 
quantity and purity of the protein samples respectively. The SETD2 R1625C mutant was generated by site-
directed mutagenesis using the QuickChange Kit (Agilent), and expressed and purified as described above. 
Note: a small amount of GST-SETD2 WT and R1625C was not treated with Precision Protease, but was 
extensively dialyzed against binding buffer then used for peptide pull-down experiments (see below).  
2.4.10 Histone Methyltransferase Assays (HMT) 
HMT assays were preformed by incubating wild type SETD2 or the R1625C variant at a final 
concentration of 500nM with 1 μg of chicken oligo-nucleosomes (EpiCypher), and 1 μCi 3H-AdoMet 
(PerkinElmer Life Sciences) in a buffer containing 50mM HEPES pH 8.0, 150mM NaCl, 2.5mM MgCl2, 1μM 
ZnCl2, and 2.5% glycerol, for 16 hours at room temperature (total reaction volume was 20μL).  The 
reactions were quenched with 0.5% TFA then spotted onto Whatman filter paper, air dried and  washed 4 
times with ~200 mLs of a sodium bicarbonate (pH 9.0) solution, air dried again and added to liquid 
scintillation vials containing 5 mLs of Ultima Gold F (PerkinElmer Life Sciences). Samples were counted for 
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1 minute each using an all-purpose Beckman Coulter liquid scintillation counter in 3H mode. A reaction 
without enzyme was used as the negative control and to determine background counts. 
2.4.11 Circular Diochroism (CD) Spectroscopy 
For CD experiments, proteins were exhaustively dialyzed into a buffer containing 20mM sodium 
phosphate (pH 7.0), 150mM sodium fluoride (NaF), and 0.2mM tris(2-carboxyethyl)phosphine (TCEP) at 
4°C. CD spectra were collected using a 0.1cm quartz cuvette and a Chirascan Plus instrument (Applied 
Photophysics Inc.) at 20 °C over the wavelength range 185-260nm with a step size of 0.5nm. A sample of 
the buffer was collected over the same wavelength scan and absorbance values were subtracted from the 
final datasets. Each sample was scanned three times and the final plots represent the average scan with 
the CD signal (in milidegrees) converted to molar ellipticity ([Θ]). For thermal melt curves, the CD 
absorbance at 207nm was collected over the temperature range from 20-95°C with 1°C temperature 
ramping and a temperature tolerance range set to 0.2°C. Proteins were diluted to 0.25mg/mL for all CD 
data collection (protein stock concentrations determined by A280).  
2.4.12 Peptide pull-downs 
A total of 50pmols of GST tagged-wild type SETD2 or the R1625C variant was incubated with 
500pmols of each biotinylated histone peptide for 1 hour at 4°C in peptide binding buffer (50mM Tris pH 
8.0, 300mM NaCl, 0.1% NP-40) supplemented with 2mM Dithiothreitol (DTT) and 1 μM ZnCl2. Following 
incubation, the protein-peptide mixture was incubated with streptavidin coated magnetic beads (Pierce), 
pre-equilibrated with peptide binding buffer, for 1 additional hour at 4°C. The beads were washed 3 times 
with peptide binding buffer and bound complexes were eluted with 1x SDS loading buffer, resolved via 
SDS-PAGE and transferred to a PVDF membrane. The membrane was probed with anti-GST antibody 
diluted to 1:4000 in 5% BSA in PBS-T. The peptides contained the budding yeast histone H3 residues 27-
45 and were mono-, di-, or trimethylated at Lys36. In this region, the human and budding yeast H3 
sequences differ by an Ala to Ser substitution at residue 31 and by an Arg to Lys substitution at residue 42.  
2.4.13 Yeast growth assays  
Parental yeast strains were transformed with indicated plasmids, and were grown to saturation in 
appropriate selection medium. Saturated cultures were diluted to an OD600 of 0.5 and 5-fold serially diluted 
and plated with or without 6-azauracil (6-AU) or plated with or without phleomycin; pictures were taken 2-3 
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days after spotting. Similarly, strains with integrated cryptic initiation cassette (as shown in Figure 2.4) were 
serially diluted and plated on -URA-HIS plates with or without galactose for 3 days to detect growth. Growth 
on –URA acted as a control for equivalent growth for all the strains.  
2.4.14 Immunofluorescence Staining for γH2A.X  
HKC cells were cultured for 16-18 hours followed by 2 Gy radiation (RS 2000 Biological Research 
Irradiator), fixed for 15 minutes in 4% paraformaldehyde, washed with cold PBS, and permeabilized (0.25% 
Triton X-100 in PBS) for 10 minutes. After blocking with 1% hydrogen peroxide then 5% BSA, cells were 
incubated with anti-γH2AX (1:500) at 4⁰C overnight. Cells were washed using PBST and incubated with 
goat anti-rabbit IgG (1:500) Cy5 1h at RT. After washing, cells were counterstained using DAPI. 
Fluorescence signals were visualized using confocal microscopy (LSM 700, Zeiss) and number of foci per 
cell were analyzed using Zen (LSM 700, Zeiss). 5 images per coverslip (total 15 images) were collected in 
three independent experiments. For the radiation colony formation assay, cells were diluted to a single cell 
suspension and 300 cells were plated on a 10 cm plate. Plates were irradiated at 0, 37, 75, 150 and 300 
rads, allowed to grow for 10 days then stained with crystal violet. Colonies were counted manually.  
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CHAPTER 3: SETD2 loss results in altered gene expression and chromatin accessibility 
3.1 Introduction
As described in Chapter 1, SETD2 is a commonly mutated gene in many different cancers. Among 
these is renal cell carcinoma. Kidney cancer is the seventh and tenth most common form of cancer in men 
and women respectively in the United States [134]. It is characterized by multiple subtypes, including clear 
cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell 
carcinoma (chRCC) [135]. Clear cell is the most common subtype, and is characterized by three major 
genetic alterations: loss of chromosome 3p [15], mutation of the VHL tumor suppressor [136], and mutation 
of chromatin modifying enzymes [18] (Figure 3.1).  SETD2 is the third most commonly mutated gene in 
ccRCC, and is mutated in 10-15% of tumors [13,14,17,18,20]. Many studies have attempted to understand 
the role of SETD2 loss in tumor development. As described in Chapter 1, SETD2 is a non-redundant histone 
methyltransferase in humans, and loss of this enzyme through mutation and loss of chromosome 3p results 
in loss of H3K36me3 in ccRCC tumors [1,17,21]. Previous work in the lab has examined H3K36me3 
deficient ccRCC tumors to determine the effect of H3K36me3 loss on chromatin organization and RNA 
processing [17]. Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE)-seq [137] was 
performed on 42 ccRCC tumor samples to determine the effect of SETD2 loss on chromatin structure. 
Figure 3.1: Rates of mutation in clear cell renal cell carcinoma [18]. ccRCC is characterized by loss of 
chromosome 3p, mutation in VHL and mutation in chromatin modifiers. 
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Approximately 7000 500bp windows showed significantly different FAIRE signal between SETD2-mutant 
and SETD2-wildtype tumors, with majority of these regions showing increased signal in the SETD2-mutant 
tumors. The regions of increased accessibility overlapped regions marked by H3K36me3 in normal kidney, 
suggesting that loss of H3K36me3 results in increased chromatin accessibility.  
 In addition to changes in chromatin accessibility, H3K36me3-deficient tumors also show changes 
in RNA processing [17].  These tumors showed increased intron retention relative to the H3K36me3 normal 
tumors. This was quantified by developing an intron retention score, which compares intronic signal to 
exonic signal. H3K36me3-deficient tumors had drastically higher intron retention scores compared to 
H3K36me3 normal tumors, particularly at transcripts which also showed increased FAIRE signal. In the 
RNA-seq data available from The Cancer Genome Atlas (TCGA) [18], SETD2 mutant tumors show 
increased levels of alternative splicing, intron retention and alternate transcription stop and start sites. 
Examining FAIRE signal at misspliced exons showed that the misspliced exons had increased chromatin 
accessibility in SETD2 mutant tumors relative to SETD2 wildtype tumors. Additionally, silencing of SETD2 
or H3K36me3 readers has been shown to result in differential exon inclusion at individual genes [71,77] as 
well as alternate transcription start site utilization [81]. Recruitment of SETD2 to particular loci is 
transcriptionally and splicing dependent, as active splicing increases the levels of H3K36me3 at individual 
genes, and H3K36me3 is found more often at intron-containing compared to intron-less genes [64]. 
 The data from TCGA and the ccRCC tumors suggested a model where loss of H3K36me3 
associated with SETD2 mutation results in increased chromatin accessibility at H3K36me3 marked regions 
through changes in nucleosome positioning. In this model, loss of nucleosome positioning may contribute 
to irregular splicing regulation, leading to altered RNA processing in SETD2 mutant tumors. This work in 
tumors contributed substantially to the understanding of SETD2 in ccRCC development, but is inherently 
limited in its ability to draw specific conclusions for SETD2 biology. This limitation is due to the complications 
of tumor biology, where tumors have additional driver and passenger mutations, and have undergone 
selective pressure in order to survive. To study the specific effect of SETD2 loss on chromatin organization 
and RNA processing, we utilized the cells described in Chapter 2, which are isogenic SETD2 wildtype and 
SETD2Δ cell lines, and conducted MNase-seq, FAIRE-seq, and RNA-seq.  
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3.2 Results 
3.2.1 SETD2 loss does not alter nucleosome positioning at the TSS 
 A nucleosome consists of a histone octomer wrapped with 147 base pairs of DNA [138]. There are 
two relationships between the octomer and the DNA: the translational relationship and the rotational 
relationship [139]. The translational relationship is the nucleosome midpoint relative to a given DNA locus, 
whereas the rotational relationship refers orientation of DNA helix on the surface of the histone octomer.  
By sequencing the DNA wrapped around the histone octomer, the translational position of the nucleosome 
can be determined. This DNA can be isolated using micrococcal nuclease (MNase), which cuts the DNA 
that is not protected by histone proteins. The DNA is then run on a gel and visualized as mono-, di-, or poly-
nucleosomes. The fraction of interest is gel purified and sequenced. This sequence defines the position of 
the nucleosome. 
 As the FAIRE data from ccRCC tumors suggests a model in which SETD2 mutation results in 
altered nucleosome positioning, we hypothesized that SETD2Δ cells would show widespread changes in 
nucleosome positioning. To test this hypothesis, SETD2 wildtype and SETD2Δ 786-O cells were treated 
with various concentrations of MNase. The DNA from the mononucleosome fraction was isolated from each 
treatment group (Figure 3.2). This was done in order to ensure equal representation of mononucleosomes 
released from chromatin at low levels of digestion, as well as mononucleosomes that require high levels of 
chromatin digestion for release. The DNA from the MNase treatment groups was then pooled, prepared 
into libraries and sequenced.  The raw sequencing files were then processed through the MNase 
sequencing pipeline described in Section 3.4.6 and analyzed using the DANPOS algorithm for calling 
nucleosome positions and properties.  
After processing the data, we first examined the nucleosome positioning at the transcription start 
site (TSS). This was chosen as the TSS has a characteristic nucleosome phasing that has previously been 
described [140]. Examining the TSS will show the quality of the MNase-seq data, and allow a comparison 
between SETD2 wildtype and SETD2Δ cells at this feature. In SETD2 wildtype cells, MNase signal at the 
TSS shows the previously described characteristic pattern of nucleosome phasing (Figure 3.3) [140]. 
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Centered slightly downstream of the TSS is the peak for the +1 nucleosome, which is well positioned across 
genes. The +2, +3, +4, and +5 nucleosomes are all easily identified, though there is loss of signal moving 
away from the TSS. This loss of signal is indicative of less positioning conservation across the population 
of nucleosomes. The -1 nucleosome is also visible, though there is an interesting phenomenon in this peak. 
Instead of one consistent peak, there is a second point within the -1 nucleosome. This likely represents a 
mixed population of nucleosomes, with some genes having a -1 nucleosome positioned ~150 bp upstream, 
and others with a -1 nucleosome ~200bp upstream (as estimated by eye). Overall, this result demonstrates 
that the MNase-seq data shows the characteristic pattern at the TSS, and is provides confidence in the 
quality of this data for future analyses.  
 We next compared the MNase-seq data at the TSS between SETD2 wildtype and SETD2Δ. Based 
on the widespread changes in chromatin accessibility seen in SETD2 mutant ccRCC tumors, we predicted 
that nucleosomes would show altered positioning in SETD2Δ cells. This was surprisingly not the case. 
SETD2 knockout cells showed remarkably similar nucleosome positioning at the TSS to 786O parental 
cells, suggesting that loss of SETD2 does not alter overall positioning at the TSS (Figure 3.4). 
Figure 3.2: MNase treatment of 786O cell lines. SETD2 wildtype (parental and TALEN treated) and 
SETD2Δ cells were treated with various units of MNase. Mononucleosomes from 0.3U-1U of MNase 
treatment were pooled and sequenced (represented by the red box).  
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Parental 
SETD2 wildtype 
SETD2Δ rep1 
SETD2Δ rep2 
Figure 3.4: SETD2 wildtype and SETD2Δ cells show similar nucleosome positioning at the TSS. Kernal-
smoothed signal for 786O cells centered at the transcription start site. X-axis represents bp from the TSS, 
y-axis represents normalized, smoothed signal. SETD2 wildtype samples are shown in black, SETD2Δ 
samples are shown in red. SETD2 wildtype refers to TALEN treated, SETD2 wildtype sample.  
Figure 3.3: 786O Parental MNase Signal at the transcription start site. Kernal-smoothed signal for 786O 
parental cells centered at the transcription start site. X-axis represents bp from the TSS, y-axis represents 
normalized, smoothed signal. 
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3.2.2 Nucleosome positioning correlates with gene expression levels 
 As H3K36me3 has been linked to gene expression [61,62], we next chose to examine whether the 
level of gene expression played a role in nucleosome positioning at the TSS. We hypothesized that the 
similarities seen in nucleosome positioning at the TSS were due to aggregating all genes, and that only 
those genes which were marked by H3K36me3 would show altered nucleosome positioning with SETD2 
loss. To test this hypothesis, we utilized RNA-seq data previously generated in the lab to separate genes 
into quartiles based on reads per kilobase million (RPKM) values. The MNase-seq data was stratified by 
these quartiles to examine the effect on nucleosome positioning at the TSS.  
Figure 3.5: MNase-seq signal at the TSS increases with increased gene expression in 786O Parental cells. 
Plots of normalized kernal-smoothed MNase signal centered at the TSS, separated by gene expression 
quartile. All graphs show signal from non-expressed genes in black. Quartile 1 is represented in blue, 
quartile 2 in green, quartile 3 in yellow, and quartile 4 in red. X-axis represents bp from the TSS. 
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 Nucleosome positioning correlates with gene expression, as the signal level increases with 
increased levels of gene expression (Figure 3.5). The effect of SETD2 loss on this phenomenon was 
examined. As in SETD2 wildtype cells, SETD2Δ cells showed increased MNase signal levels with increased 
gene expression (Figure 3.6). The level of signal matches that of SETD2 wildtype cells. Thus, we can 
conclude that loss of SETD2 does not alter signal at the TSS, regardless of the level of gene expression.  
3.2.3 Internal exons are characterized by a well-placed nucleosome 
 SETD2 mutant ccRCC tumors showed altered chromatin accessibility at exons, particularly those 
with splicing defects [17]. The hypothesis was that the increase in FAIRE signal was due to loss of the 
H3K36me3 marked nucleosome present in SETD2 wildtype cells. To test this hypothesis, we examined 
MNase signal at internal exons: exons which are neither the first nor the last in the gene. These exons have 
a MNase peak, indicative of a well-placed nucleosome, immediately after the exon start (Figure 3.7). 
Surprisingly, this well-placed nucleosome is also present in SETD2Δ cells. This suggests that nucleosome 
positioning at internal exons is not affected by SETD2 loss.  
Figure 3.6: MNase-seq signal at the TSS increases with increased gene expression in SETD2Δ cells. Plots 
of normalized kernal-smoothed MNase-seq signal centered at the TSS, separated by gene expression 
quartile. Non-expressed genes are represented in black, quartile 1 in blue, quartile 2 in green, quartile 3 in 
yellow, and quartile 4 in red. Signal is kernal-smoothed  
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3.2.4 SETD2 loss results in changes to chromatin accessibility 
 As the analysis of the MNase data did not show alterations in nucleosome positioning at the 
examined genomic features, we decided to study chromatin using the same technique utilized in the ccRCC 
tumor study: FAIRE. FAIRE-seq was performed on SETD2 wildtype and SETD2Δ human kidney cells 
(HKC) [131]. The data was analyzed as 500bp windows. ~8500 differential regions were identified using a 
t-test (p<0.05). Of these differential regions, ~5000 show higher FAIRE signal in SETD2Δ cells, while ~3000 
show higher accessibility in wildtype cells (Figure 3.8A). This suggests loss of SETD2 is associated with 
increased chromatin accessibility.  
 By combining the FAIRE data and MNase data, the properties of nucleosomes within differential 
FAIRE regions can be examined. Regions which showed increased accessibility in SETD2Δ cells were 
overlapped with nucleosomes and examined for nucleosome properties, including occupancy and 
positional conservation. Occupancy measures how often a nucleosome is present in a sample, and 
positional conservation measures the variation in the center of a nucleosome peak. Nucleosomes in regions 
of increased accessibility in SETD2Δ cells show decreased positional conservation (Figure 3.8B), but 
Figure 3.7: Internal exons are marked with a well-positioned nucleosome which is unaffected by SETD2 
loss. Average MNase-seq signal in SETD2 wildtype (black) and SETD2Δ (red) cells is shown, centered at 
the start of an internal exon. 
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surprisingly had higher occupancy (Figure 3.8C). This suggests that nucleosomes called in the regions of 
increased chromatin accessibility have a higher percentage sequencing reads assigned to each 
nucleosome in SETD2Δ samples, but these nucleosomes are less well positioned than in the SETD2 
wildtype samples. This is supported by the fact that there are fewer nucleosomes in these regions (Figure 
3.8D). Overall, this suggests that in these regions, wider variation in nucleosome positioning results in more 
sequencing reads being assigned to an individual, less well positioned nucleosome, while the total number 
of nucleosomes in this region is decreased.  
3.2.5 SETD2 loss results in few overall transcription changes 
 In addition to examining the role of SETD2 in chromatin organization, the effect of SETD2 loss on 
transcription was examined. As SETD2 mutation in ccRCC results in widespread transcription defects, we 
hypothesized that isogenic loss of SETD2 in ccRCC cell lines would result in high levels of RNA processing 
defects, as well as changes in gene expression. We tested this by conducting RNA-seq in both 786O 
SETD2 wildtype and SETD2Δ cells and HKC SETD2 wildtype and SETD2Δ cells. Using this data we are 
Figure 3.8: SETD2 loss results in increased chromatin accessibility with altered nucleosome properties. A) 
heatmap of FAIRE signal for significantly different 500bp windows (p=0.05). B) Boxplot of fuzziness score 
generated by DANPOS for nucleosomes in regions of increased FAIRE accessibility in SETD2Δ cells. 
Higher score represents decreased positional conservation. SETD2Δ samples are colored in red. C) 
Boxplot of Occupancy in regions of increased FAIRE accessibility in SETD2Δ cells. SETD2Δ samples are 
colored in red. D) Number of nucleosomes present in regions of increased FAIRE accessibility in SETD2Δ 
cells. 
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able to compare SETD2 wildtype versus SETD2Δ both within a genetic background and across different 
cell types.  
 In order to make these comparisons, we used DESeq2 [141], an industry standard. DESeq2 uses 
raw read counts aligned to genes as an input, estimates size factors to account for variation in sequencing 
depth, estimates dispersion values for each gene to account for sequencing bias across genes, before 
finally fitting a generalized linear model. Using this model, differentially expressed genes are determined. 
 The first comparison was made within the cell lines. Comparing between HKC SETD2 wildtype and 
HKC SETD2Δ cells identified ~360 differentially expressed genes (adjusted p<0.1) (Figure 3.9). Of these, 
185 had increased expression in SETD2Δ cells, while 174 had decreased expression. When comparing 
the expression levels of the differential genes, it is clear that differentially expressed genes have a range 
of expression, and that overall expression changes are small, with only 6 genes showing greater than a 2 
fold change. This suggests than in an HKC background, only a small number of genes have altered gene 
levels associated with SETD2 loss, and the majority of changes in gene levels are small.  
 Next, the same comparisons were made in 786O SETD2 wildtype and SETD2Δ cells. In the 786O 
background, only ~140 differentially expressed genes were identified (adjusted p-value <0.1) (Figure 3.9). 
Of these, 75 genes had increased expression in SETD2Δ cells, and 66 had decreased expression. Only 8 
Figure 3.9: SETD2 wildtype versus SETD2Δ comparison identifies differential gene expression. MA plot 
showing expression changes between wildtype and knockout samples. Genes with adjusted p-value <0.1 
colored in red. x-axis represents average expression of each change, y-axis represents the log fold change 
between SETD2 wildtype and SETD2Δ. Left: HKC, Right: 786O 
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of these genes showed greater than a 2 fold change. This data is very similar to the HKC data, supporting 
the finding that SETD2 loss does not result in widespread alterations in RNA abundance.  
 Comparisons were made across genetic backgrounds to test if changes in RNA abundance due to 
SETD2 loss were consistent between samples. The lists of differential genes found in HKC and 786O were 
overlapped to identify genes which are consistently altered by SETD2 loss. There was very little overlap 
between genes which were downregulated in SETD2Δ cells, as only 3 genes were common between 786O 
and HKC (Figure 3.10). Upregulated genes had similar results. In fact, 4 genes which were downregulated 
in 786O were upregulated in HKC, and 2 genes which were downregulated in HKC were upregulated in 
786O. This result suggests that RNA abundance changes which occur with SETD2 loss are not consistent, 
and are affected by genetic background.   
3.2.6 SETD2Δ samples have higher variation in RNA abundance than their wildtype counterparts. 
As the differential genes between samples showed little overlap, similarity between replicates of 
SETD2Δ samples was examined. The Euclidean distance between all samples for both HKC and 786O 
was calculated, and the two wildtype replicates for each sample had a smaller Euclidean distance between 
them than the two SETD2Δ replicates (Figure 3.11A). In particular, the Euclidean distance between 786O  
Figure 3.10 786O and HKC differential genes show little overlap. Venn diagram representing the 
intersection of genes identified to be upregulated or downregulated with SETD2 loss in either 786O or HKC.  
46 
 
  
Figure 3.11: SETD2Δ replicates are more dissimilar than their wildtype counterparts. A) Euclidean distance 
between samples. B) Poisson distance between samples.  
A 
B 
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SETD2Δ samples was similar in magnitude to the distance between SETD2Δ and SETD2 wildtype cells. 
Similar analysis using the Poisson distance showed the same result (Figure 3.11B). In addition to 
calculating a distance metric, a principle component analysis for both cell types was completed. Principal 
component 1 consistently separated SETD2 wildtype from SETD2Δ samples, and accounted for 67% and 
60% of the variance in HKC and 786O respectively (Figure 3.12).  In both backgrounds, principle 
component 2 separated the two replicates for SETD2Δ, and accounted for 24% of the variance in HKC and 
32% of the variance in 786O. This result indicates that though the main driver of variation between these 
samples is SETD2 status, a substantial driver is still variation within SETD2Δ replicates.  
 We hypothesized that the substantial variation within SETD2Δ replicates contributed to the low 
number of significant differentially expressed genes. To examine this, it is necessary to find the change in 
gene expression for each SETD2Δ replicate. The log2 ratio of the gene counts for each HKC SETD2Δ 
sample to the wildtype average was calculated, then compared across replicates. In contrast to the 6 genes 
which showed greater than a 2 fold change in the differential expression analysis, ~3000 genes had a >2 
fold change when a single SETD2Δ sample was compared to both wildtype samples (Figure 3.13). Of 
these, 1336 overlap between SETD2Δ replicates. Additionally, 81 genes actually change in different 
directions. Unfortunately, using only one sample limits the ability to make statistically significant 
determinations, but this data indicates that large changes in gene expression do occur with SETD2 loss, 
and these changes are not consistent across samples.  
This is further supported by analyses done with combined HKC and 786O datasets. Differential 
expression analysis shows that very few differential genes are identified in a combined data set (Figure 
3.14A), and principal component analysis shows that principal component 1 separates HKC and 786O by 
background, and accounts for 92% of the variance (Figure 3.14B). This indicates differences in genetic 
background are more substantial than gene expressions changes associated with SETD2 loss.  
3.2.7 Intron retention occurs in SETD2 wildtype and SETD2Δ cells  
Altered RNA processing is a feature of SETD2 mutant tumors [17]. To study RNA processing, we 
utilized a previously published score to measure intron retention [17]. This score calculates the intronic 
coverage over the total gene coverage in order to determine what fraction of RNA-seq reads in a gene 
occur in introns. This score was calculated for each gene in the HKC and 786O samples. Surprisingly, all  
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Figure 3.13: HKC SETD2Δ replicates each show high levels of gene expression changes compared to 
wildtype samples. Graphs show genes with >2 fold change in RNA abundance, rank ordered by expression 
change. Left: replicate 1, Right: replicate 2. Both replicates are compared to the average wildtype signal.   
Figure 3.12: Principle component analysis of RNAseq data shows wide variation between SETD2Δ 
replicates. Principle component analysis of 786O (left) and HKC (right) RNAseq data. 
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samples showed a similar distribution of intron retention scores (IRS) (Figure 3.15).  
Despite the similarities in overall distribution of IRS, comparison between 786O SETD2 wildtype 
and SETD2Δ cells shows 1179 genes with significantly different IRS (t-test p<0.05 post filtering). The 
majority of these genes show small changes in IRS (Figure 3.16A), with only 273 genes having an absolute 
value of difference between wildtype IRS and SETD2Δ IRS >0.05 (Figure 3.16B). Of these genes, the 
majority show an increased IRS in SETD2Δ cells. When comparing changes in intron retention score to 
gene expression levels (as measured by reads per kilobase million (RPKM)), it is clear that genes which 
show high changes in IRS between wildtype and knockout are also lowly expressed in both SETD2 wildtype  
(Figure 3.16C) and SETD2Δ (Figure 3.16D) samples. This data suggests that changes in intron retention 
do occur with SETD2 loss, however, the majority of genes are not substantially affected.    
  
Figure 3.14: Gene expression differences between HKC and 786O are greater than those associated with 
SETD2 loss. A) MA plot showing expression changes between wildtype and SETD2Δ samples. Genes with 
adjusted p-value <0.1 colored in red. x-axis represents average expression of each gene, y-axis represents 
the log fold change between SETD2 wildtype and SETD2Δ samples. B) Principle component analysis of 
combined HKC and 786O data sets 
A B 
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Figure 3.16: Intron retention differences between SETD2 wildtype and SETD2Δ samples are small and 
occur at lowly expressed genes. A) Rank-ordered representation of knockout IRS – wildtype IRS (ΔIRS), 
where each line represents 1 gene. B) Filtered results of A for those with a |ΔIRS|>0.05 C) Genes from B 
plotted by ΔIRS versus SETD2 wildtype average RPKM D) Genes from B plotted by ΔIRS versus SETD2Δ 
average RPKM  
Figure 3.15: Intron retention score is similar across SETD2 wildtype and SETD2Δ samples. Left: Histogram 
of 786O IRS for each sample. Right: Histogram of HKC IRS for each sample. 
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3.3 Discussion  
Multiple lines of evidence indicate the importance of SETD2 mutation in ccRCC development. 
SETD2 mutation correlates with worse cancer-specific survival in ccRCC [103]. Studies which explored 
intratumor heterogeneity have identified independent mutations in SETD2 across multiple subsections of 
an individual tumor, suggesting that SETD2 mutation is a critical and selected event in ccRCC development 
[20]. Understanding how SETD2 loss contributes to ccRCC development is key to understanding this 
disease, as well as identifying new therapeutic opportunities. 
Previous work has shown that in ccRCC tumors, H3K36me3 loss results in altered chromatin 
accessibility and RNA processing [17]. The work in this chapter builds on this, and suggests that the role 
of SETD2 in these processes may be somewhat more nuanced than previously suspected. The initial 
hypothesis for changes in chromatin accessibility seen in ccRCC tumors was that H3K36me3 marked 
nucleosomes were no longer properly positioned, particularly at internal exons which were misspliced. This 
model is not supported by the MNase-seq results. As internal exons and TSS show no alterations in 
nucleosome positioning associated with SETD2, these loci do not rely on H3K36e3 marking for positioning 
cues. Changes in chromatin accessibility are still found in SETD2Δ cells, indicating that this is a feature 
common to SETD2 loss, not just a feature of ccRCC SETD2 mutant tumors. Furthermore, nucleosome 
properties at regions of increased chromatin accessibility are altered. Studies in other models have shown 
than changes in chromatin accessibility can occur without changes in nucleosome positioning due to altered 
nucleosome properties [142]. In that study, regions with increased FAIRE signal had MNase signal 
suggesting well positioned nucleosomes. It is possible that in ccRCC tumors, the increased chromatin 
accessibility is due to altered nucleosome properties, rather than changes in positioning. This model would 
be supported by the chromatin accessibility and nucleosome positioning data described above.  
H3K36me3 deficient ccRCC tumors also showed widespread alterations in RNA processing, with 
nearly 25% of expressed genes showing alterations [17]. Many studies conducted since this result was 
published have examined the role of SETD2 in RNA processing, with conflicting results. In one study of 
SETD2Δ cells, altered exon utilization and differential splicing occurred [21]. However, in a study of SETD2 
silencing, exon usage and intron retention were unaltered [74]. We have found that intron retention is 
increased with SETD2 loss, but the number of genes as well as the level of expression of these genes is 
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low. Additionally, large changes in RNA abundance did not occur. One potential explanation for this is cell 
cycle related. Certain genes have periodic expression which correlate with cell cycle stage [143]. 
H3K36me3 is enriched over the gene body of these genes. H3K36me3 levels are also highest in G1, and 
decrease with the cell cycle [89]. As the RNA for this study was taken from an unsynchronized population, 
it is possible that cell cycle changes in H3K36me3 and associated changes in gene expression are lost in 
the total RNA.  Future studies may consider synchronizing cells to ensure comparisons are made within 
the same cell cycle stage.  
Our studies also suggest substantial variation between SETD2Δ replicates. As described in 
Chapter 2, the role of H3K36me3 in DNA damage is an area of active study [84,86,90]. As the cells used 
for this study were single cell sorted, grown as clones, then passaged for experiments, DNA damage may 
have occurred and been improperly repaired during this process. This would result in clonal variation 
between replicates. As shown above, changes in genetic background contribute more to variation in RNA 
abundance than loss of SETD2 (Figure 3.14). To further explore this phenomenon, studies using an 
inducible SETD2 loss through protein degradation are being explored. Using a system in which SETD2 loss 
occurs in a systematic, time course manor would allow comparisons to be made minutes, hours, and days 
after SETD2 loss. This would allow the dynamics of H3K36me3, RNA processing and chromatin 
accessibility changes to be further explored, as well as provide context for early ccRCC tumor development.  
The results described in this chapter suggest that SETD2 has a role in chromatin accessibility and 
RNA processing, but also paint a complicated picture of regulation. Further analysis of all generated 
datasets are necessary for a complete understanding of the effect of SETD2 loss on these features. 
Identifying misspliced exons and other alterations in RNA processing will further our understanding of the 
role of SETD2 in RNA processing. Additionally, once genes with aberrant processing are identified, FAIRE 
and MNase signal can be examined at these exon or genes. This will allow us to expand the model of 
nucleosome positioning and chromatin accessibility in RNA processing originally proposed to more 
accurately describe biological events in the cell.  
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3.4 Methods  
3.4.1 Cell Lines Used 
786O and HKC SETD2Δ generation was previously described in Section 2.4.2. For MNase-seq, 
786O parental, TALEN-treated, and two SETD2Δ cell lines were used. TALEN-treated refers to cells 
which were treated with both TALEN vectors, but did not show loss of H3K36me3 by dot blot and were 
verified to have intact SETD2 sequence by allelic sequencing. For FAIRE-seq, HKC parental, HKC left-
TALEN treated, HKC SETD2Δ 1, and HKC SETD2Δ 2 cell lines were used. HKC left-TALEN treated refers 
to cells which were treated with only the left targeting TALEN construct, and did not show loss of 
H3K36me3 by dot blot and were verified to have intact SETD2 sequence by allelic sequencing. RNA-seq 
was done using all the above cell lines.  
3.4.2 MNase Treatment 
 786O parental, 786O TALEN-treated, 786O SETD2Δ replicate 1 and 786O SETD2Δ replicate 2 
cells were grown on 15cm plates, isolated and washed with cold PBS, and resuspended in resuspension 
buffer (RSB: 10mM Tris-HCl pH 7.4, 10mM NaCl, 3mM MgCl2). The suspension was incubated on ice for 
10 minutes, before adding NP-40 (final concentration 1%) and nutating on ice 30 minutes. The samples 
were centrifuged (3000RPM 4°C 5 minutes), washed 2x with RSB, and resuspended in 200uL of MNase 
reaction buffer (10mM Tris-HCl pH7.5, 5mM MgCl2, 5mM CaCl2 0.1mM PMSF, 0.5mM DTT). The OD 260 
for each sample was determined using the Nanodrop 1000 Spectrophotometer, and samples were diluted 
to a OD 260 of 1. The desired units of MNase were added (0.1, 0.2, 0.3 0.4, 0.5, 0.8, 1, 2 units), and 
samples were placed at 37°C for 10 minutes. The digestion reaction was stopped by addition of 10mM 
EDTA/EGTA, then RNAse and Proteinase K treated. The DNA was extracted using a phenol-chloroform 
extraction, then run on a 2% agarose gel to assess digestion levels. After digestion was verified, DNA was 
run on a new agarose gel, and mononucleosome DNA from 0.3U – 1U treatment groups was pooled, 
prepared into libraries (described below) and sequenced.  
3.4.3 FAIRE 
HKC parental, HKC left-TALEN treated, HKC SETD2Δ replicate 1, and HKC SETD2Δ replicate 2 
cells were treated with 1% formaldehyde for 7 minutes, inactivated with 125mM glycine, scraped to collect, 
washed with cold PBS, and resuspended in FAIRE lysis buffer (10mM Tris-HCl pH 8.0, 2% Triton X-100, 
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1% SDS, 100mM NaCl, 1mM EDTA). The sample was sonicated to an average fragment size of ~400bp. 
DNA was phenol-chloroform extracted, and prepared into libraries as described below.  
3.4.4 cDNA generation for RNA sequencing 
Total RNA was isolated from HKC parental, HKC left-talen treated, HKC SETD2Δ replicate 1, and 
HKC SETD2Δ replicate 2 using TRIzol reagent (Ambion RNA 15596-026) following the manufacturers 
protocol. RNA was Ribo-Minus treated (Ribo-Minus Eukaryote System v2, Life Technologies A15026), 
fragmented (Ambion RNA by Life Technologies Fragmentation Reagents, AM8740), first strand 
synthesized using random primers, RNase H treated and second strand synthesized. 100ng of cDNA was 
used for library preparation as described below. 786O sequencing data was previously generated by Dr. 
Kathryn Hacker [144].  
3.4.5 Library preparation 
 Sequencing libraries for MNase DNA, cDNA, and FAIRE DNA all followed the standard Illumina 
sequencing protocol. For MNase-seq, 100ng of DNA was used as input. For RNA-seq, 80-100ng of cDNA 
was used as input. For FAIRE-seq 100ng of DNA was used as input. DNA was blunted, purified using 
Ampure XP beads, A-tailed, adapter ligated, purified using Ampure beads two additional times, before PCR 
amplification (12 cycles for MNase, 12 cycles for RNA, 15 cycles for FAIRE) and one additional purification. 
Final libraries were submitted as a pool to the UNC High Throughput Sequencing Facility (HTSF) for 
sequencing. MNase-seq utilized 4 lanes of paired-end 50bp reads. RNAseq utilized 2 lanes of paired-end 
50 base pair reads. FAIRE-seq utilized 1 lane of paired-end 50 base pair reads.  
3.4.6 Sequencing pipeline and data processing 
 After fastq files were obtained from the HTSF, the files were processed to remove adapters using 
TagDust [145].  Paired-end sequences were synchronized to each other, then aligned to the genome using 
Bowtie [146].  The bowtie output files were convered to BAM files using samtools [147], then filtered for 
properly mapped reads. These files were used to generate downstream files for additional analyses. For 
MNase-seq, BAM files were used by DANPOS [148] (version 2.1.3) to call nucleosomes and nucleosome 
properties. Differential FAIRE regions were called by comparing signal in 500 base pair genomic windows 
between SETD2 wildtype and SETD2Δ samples using a t-test, and a p-value cutoff of 0.05.  Nucleosomes 
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within a FAIRE region required a 1 base pair overlap between the 500 base pair window and the DANPOS 
called nucleosome. 
3.4.7 MNase signal at specific genomic features 
MNase signal plots at specific genomic features were generated using R. Wiggle files were input 
into Zinba [149] to create .coord files for the desired feature using the coord.spbc function. This .coord file 
was collapsed into a single profile for the feature, which was graphed using standard R parameters. For 
kernel-smoothed graphs, the ksmooth function within R was utilized. Features files were created by 
downloading genomic information from the UCSC table browser [150], and formatting for Zinba use. TSS 
files were generated from TSS data downloaded from UCSC, with 3 kilobases added to each end of the 
annotated TSS, accounting for standedness. Internal exons were generated by downloading an exon list, 
removing the first and last exon for each gene, and add 1.5 kilobases to each end of the exon start, 
accounting for strandedness.  
3.4.8 RNA-seq analysis 
Differential expression analysis was determined using DESeq2 [141] with the default parameters. 
HTSeq gene counts were used as the input for DESeq2 [151]. Differential genes were called at adjusted p-
value<0.1. Euclidean distance, Poisson Distance and Principal Component analysis were all completed 
using DESeq2 with rlog transformed data. Reads per kilobase-million (RPKM) for individual genes were 
calculated using an in-house script. Intron retention scores were calculated as previously described [17]. 
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CHAPTER 4: SRI alteration does not affect genomic placement of H3K36me3
4.1 Introduction 
The overall goal of this dissertation is to contribute to the understanding of the role of SETD2 
mutation in ccRCC development. Chapter 2 described the generation of isogenic SETD2 wildtype and 
SETD2Δ cells, as well as the reintroduction of tSETD2 and two point mutations. Chapter 3 studied the effect 
of SETD2 loss on chromatin organization and RNA processing. These studies have contributed to our 
understanding of the effect of SETD2 loss on specific phenotypes, but did not explore the effect of loss and 
mutation on the original described role of SETD2 as a histone methyltransferase. 
SETD2 mutations in ccRCC can be placed into 3 general categories: early inactivating, SET domain 
mutations, and SRI alterations (Figure 4.1A). In Chapter 2, we examined the effect of TALEN inactivation 
(representative of early inactivating), one SET domain mutation (R1625C), and one SRI domain mutation 
(R2501H) on methyltransferase activity. The R1625C mutation disrupts the catalytic activity of SETD2 
(Figure 2.2, [152]). The R2510H mutation in the SRI domain did not impair global restoration of H3K36me3, 
as measured by immunohistochemistry and western blot (Figure 2.2, [152]). This level of analysis does not, 
however, determine how genomic placement of this mark is affected.  
In addition to the SRI point mutant, a new mutation was generated: T2457*. This mutation converts 
T2457, the first amino acid of the SRI domain, to a stop codon, effectively removing this domain. We 
hypothesized that alteration of the SRI domain, though mutation or deletion, would alter genomic positioning 
of the H3K36me3 mark. To test this hypothesis, we conducted chromatin immunoprecipitation for 
H3K36me3 across our cell lines. 
4.2 Results 
4.2.1 The SRI domain of SETD2 is required for interaction with RNAPII but dispensable for 
methylation 
As described in Chapter 2, we have generated a series of SETD2Δ cells using TAL effector 
nucleases [152]. Using these cells, we reintroduced a truncated SETD2 construct, tSETD2 (amino acids 
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1323–2564). tSETD2 includes all known functional domains of SETD2 (Figure 4.1B) and transient 
expression of tSETD2 restores H3K36me3 globally, [152]. In contrast to the experiments of Chapter 2, 
which were conducted in cells transiently expressing tSETD2 and mutants, we transduced SETD2Δ cells 
with lentivirus and selected for stable expression of tSETD2 and the mutant constructs. The stable 
expression construct has an HA-tag on the N-terminus of tSETD2, and a C-terminal GFP sequence. GFP 
and tSETD2 (or mutant tSETD2) are co-transcribed, but separated by a 2A peptide. The 2A peptide is an 
18 amino acid sequence found in the aphthovirus foot-and-mouth disease virus [153]. This sequence 
interacts with the ribosome to promote hydrolysis of the peptidyl(2A)-tRNAGly ester linkage, releasing the 
synthesized polypeptide, while proceeding to translate the remaining RNA sequence [154]. This system 
has been developed in many cellular backgrounds as a way to ensure equal expression of multiple peptides 
[155,156].  
Using the tSETD2-2A-GFP system, we transduced 786O SETD2Δ cells with the construct of 
choice, selected with antibiotics, and used flow cytometry cell sorting to select GFP positive cells. GFP 
expression levels post-sorting were re-examined by flow cytometry (Figure 4.2). The percent GFP positive 
cells varied between samples. Based on this, the level of GFP expression was verified by western blot 
(Figure 4.3). GFP expression levels tracked with the percent GFP positive cells determine by flow 
cytometry, with SETD2Δ+EV having the highest level of GFP, and SETD2Δ+R1625C having the lowest. 
Figure 4.1: SETD2 mutations in ccRCC fall into three categories. A) ccRCC SETD2 mutations annotated 
in cBioPortal [11,12]. Colored boxes represent mutation types. Black = early inactivating, Red = SET 
domain, Green = SRI domain B) Schematic of tSETD2 construct and mutations used for ChIP-seq 
A 
B 
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Given that GFP levels should match tSETD2 levels, we also blotted for the HA tag present in the constructs.  
Surprisingly, tSETD2 had the lowest levels of expression, despite similar levels of GFP to other samples 
(Figure 4.3). The level of HA tag was normalized to the tubulin loading control, and comparisons between 
samples show large levels of variation. SETD2Δ+tSETD2 has the lowest expression, while 
SETD2Δ+T2457* expression is very high.  
We next examined the restoration of H3K36me3 in SETD2Δ cells by stable expression of the 
various mutants using western blotting (Figure 4.4). As previously found with transient expression, SETD2Δ 
and cells stably expressing the R1625C point mutation both lack H3K36me3 (Figure 2.2, [152]). 
Additionally, stable tSETD2 expression restores H3K36me3 to wildtype levels, as does the stable 
expression of the R2510H point mutation. We predicted that the SRI deletion would not be capable of 
trimethylation. Surprisingly, stable expression of the T2457* mutant in SETD2Δ cells restores H3K36me3. 
Figure 4.2: Stable Expression of SETD2 mutants with GFP shows substantial GFP positive population. A)  
Histogram of GFP Signal in individual samples and a non-transfected negative control. B) Table of percent 
of the total population which is GFP positive C) Overlapped tracks of A, with gating box used to determine 
percent positive shown in blue.   
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Both the R2510H SRI point mutation and the T2457* SRI deletion were trimethylation competent, 
despite predicted disruption of the interaction between tSETD2 and RNA Polymerase II (RNAPII). To further 
explore the effect of mutation on this relationship, we performed a co-immunoprecipitation for the HA tag 
and RNAPII. Due to low levels of tSETD2 in 786O stable expressing cells, this was conducted in HKC 
stable expressing cells, as well as 293T transient expressing cells for verification. As expected, RNAPII co-
immunoprecipitated with HA in tSETD2 expressing cells, as well as R1625C expressing cells (Figure 4.5). 
RNAPII did not co-immunoprecipitate with either R2510H or T2457*, despite both having a similar HA 
immunoprecipitation efficiency to tSETD2. This was true in both cellular backgrounds.   
It is possible that the failure to interact by co-immunoprecipitation is due to the absence of chromatin 
as a substrate. To test whether chromatin is required for RNAPII to interact with the SRI altered tSETD2, 
Figure 4.3: SETD2 expression varies between samples. Left: Western for HA tag (l.e. = low exposure, h.e. 
= high exposure) tubulin loading control and GFP. Right: Quantification of HA levels relative to tubulin.  
Figure 4.4: SRI domain alteration does not diminish H3K36 trimethylation levels. Left: Histone western blot 
for H3K36me3 and H3. Right: Quantification of H3K36me3 relative to H3 levels. 
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an HA immunoprecipitation was conducted on a chromatin extract. Unlike the experiments done on cellular 
extracts, RNAPII co-immunoprecipitated in all samples, including the negative control (Figure 4.6). There 
was no enrichment for RNAPII in either the tSETD2 or the R1625C samples, despite efficient pulldown of 
HA. This suggests that the presence of chromatin in the extract does not stabilize the interaction between 
RNAPII and tSETD2.  
4.2.2 ChIP-Rx allows quantitative comparisons between samples 
Though the western blot confirms H3K36me3 is present, there is no evidence for or against proper 
targeting. We hypothesize that as the R2510H and T2457* mutants do not interact with RNAPII (as 
measured by co-immunoprecipitation), H3K36me3 will be mistargeted in SETD2Δ cells expressing these 
mutants. This was tested using a modified form of chromatin immunoprecipitation sequencing (ChIP-seq) 
known as ChIP-Rx [157]. Chromatin Immunoprecipitation with a Reference Exogenous Genome (ChIP-Rx) 
allows genome-wide quantitative comparisons of histone modification status across cell populations though 
the use of a reference epigenome. This reference epigenome is one which contains the specific histone 
modification of interest, and is added equally to each sample. The equal addition of the exogenous genome 
to each sample permits normalization to the amount of exogenous DNA in the sample, and allows for 
quantitative comparisons to be made across samples. This technique was chosen over standard ChIP as 
Figure 4.5: SRI domain is required for interaction between tSETD2 and RNAPII. Left: Co-
immunoprecipitation in HKC stable expression cells. Right: Co-immunoprecipitation in 293T transient 
expression cells. Lysate represents whole cell extract used as input for immunoprecipitation. HA-IP 
represents final sample after immunoprecipitation with anti-HA antibody. Anti-HA and anti-RNAPII refer to 
the antibody probe used for the western blot.  
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differences between SRI altered tSETD2, tSETD2 and wildtype SETD2 may be in terms of levels of 
H3K36me3.  
For ChIP-Rx, the exogenous epigenome chosen was the Drosophila S2 cell epigenome, which also 
has H3K36me3. S2 nuclei were added at a 1:2 ratio prior to sonication and immunoprecipitation, as this 
ensures equal sonication and pulldown efficiency for both the sample and the S2 spike-in control (Figure 
4.7).  After sequencing, the raw files were aligned to both the Drosophila and human genomes to determine 
the total number of reads for each species. This allows for determination of the normalization constant 
(α=1/count of reads (in millions) aligning to the Drosophila genome). Comparisons across inputs for each 
sample shows a similar percentage of reads aligned to the Drosophila genome of the total number of reads 
(Figure 4.8). This is expected, as the same number of Drosophila cells were added to an identical number 
of 786O cells. ANOVA testing shows there is no difference between the percent of Drosophila reads across 
inputs (p=0.935). In H3K36me3 competent samples, the percent of Drosophila reads mapped to each 
immunoprecipitation sample is similar to the level in the input, though t-test comparison between wildtype 
input and sample, as well as between tSETD2 input and sample do meet statistical significance (p=0.024 
Figure 4.7: ChIP-Rx uses Drosophila S2 cells as a normalization for H3K36me3 ChIP-seq. Schematic of 
experimental design for H3K36me3 ChIP-Rx experiment.  
Figure 4.6: Chromatin does not stabilize interaction between tSETD2 and RNAPII. Lysate represents whole 
cell extract used as input for immunoprecipitation. HA-IP represents final sample after immunoprecipitation 
with anti-HA antibody. Anti-HA and anti-RNAPII refer to the antibody probe used for the western blot.   
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and p=0.0090 respectively). Interestingly, H3K36me3 deficient samples show a substantial increase in the 
percent of reads mapping to Drosophila, with 11.3% of reads in SETD2Δ and 14.1% of reads in 
SETD2Δ+R1625C mapping to the Drosophila genome (p=0.0022 and p=0.0083 versus input). This is 
expected, as the Drosophila cells will have the H3K36me3 mark present, and will therefore be enriched 
over the H3K36me3 deficient SETD2Δ cells in the pulldown.  
4.2.3 Wildtype H3K36me3 signal is enriched at coding exons and correlates with gene expression 
Previous studies have examined H3K36me3 localization across the genome, however, this is the 
first large scale H3K36me3 study conducted with a spike-in normalization strategy. This enables high 
quality analysis of H3K36me3 levels to build upon previously published findings. Initial data analysis 
focused on genic regions, as H3K36me3 has been linked to transcription [61,158,159]. Metagene analysis 
Figure 4.8: H3K36me3 deficient cells show higher levels of Drosophila DNA. Percent of total reads mapping 
to the Drosophila genome by sample. Input (blue) is the sample prior to immunoprecipitation, IP (orange) 
is the sample after immunoprecipitation. 
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of genes shows that H3K36me3 increases along the length of the gene from transcription start site (TSS) 
to transcription termination site (TTS) (Figure 4.9), similar to previous findings [1,160,161].  
When examining signal at specific genomic features, coding exons showed the highest level of 
signal enrichment compared to input, with the other genic features also showing increased signal relative 
to input (Figure 4.10). Promoters and intergenic regions showed the least signal enrichment. This result 
supports previous analyses which showed differential H3K36me3 levels at exons and introns [70], as well 
as emphasizing the genic localization of H3K36me3.  
As signal is most enriched at coding exons, the features of this signal were further explored. Signal 
at coding exons is not dependent on exon length, as there is not increased signal for longer exons (Figure 
4.11). High levels of H3K36me3 are found at long and short exons alike, as are low levels of H3K36me3. 
The majority of exons are between 30-1000bp in length, and the signal at these exons is shows mostly 
small differences between sample and input.  
 In addition to the overall genomic localization of H3K36me3, the effect of gene expression on 
H3K36me3 levels was examined. RPKM data generated in Chapter 3 was correlated with average 
H3K36me3 per gene. H3K36me3 levels distributed by RPKM quartiles display a positive correlation, with 
Figure 4.9: 786O + empty vector shows increasing H3K36me3 signal along the length of the gene. 
Metagene signal of 786O+EV. Average signal (line) for 786O+EV samples 1000 bp upstream of the TSS, 
from TSS to TTS, and 1000bp downstream of the TTS. Dotted lines represent TSS (left) and TTS (right). 
Line represents the average signal for all genes, averaged across replicates. Shading represents standard 
deviation between 786O+EV replicates 
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Figure 4.11: Coding Exons show highest level of H3K36me3 enrichment. Boxplots for average signal at 
each feature. Signal was calculated by dividing H3K36me3 normalized values per feature by the matched 
input, averaging replicate values, then log2 transformed for plotting. Values greater than 0 (dotted line) are 
enriched over input. 
Figure 4.10: H3K36me3 levels are not correlated with exon length. Left: Scatter plot of exon length (log2 
transformed) by Sample/Input for 786O+EV samples (log2 transformed). Color indicates density of points 
at the location, range from blue (low density) to red (high density). Right: Histogram of exon length (log2 
transformed). 
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increased gene expression correlating with increased methylation (Figure 4.12A). The reciprocal 
comparison also shows this trend (Figure 4.12B).  
4.2.4 SETD2Δ results in total loss of H3K36me3 
The benefit of ChIP-Rx is the normalization factor provided by the Drosophila cells. The addition of 
cells which have the positive mark decreases the likelihood of finding false positives in the ChIP-seq dataset 
for SETD2Δ cells. Based on this assumption, H3K36me3 ChIP was conducted in the SETD2Δ cells to 
determine if loss of SETD2 results in retargeting of trimethylation to non-coding regions. We first examined 
signal at genic regions, as was done for 786O+EV samples. Unlike the SETD2 wildtype cells, SETD2Δ+EV 
cells show near complete loss of signal at genes (Figure 4.13A).  
When examining signal at specific genomic features, the generalized loss of H3K36me3 signal can 
be clearly observed (Figure 4.13B). Nearly all the data has a log2 ratio of Sample/Input less than 0, 
indicating that few data points show higher signal in the H3K36me3 ChIP than the matched input.  
Comparing signal specifically at coding exons shows very little signal greater than zero in the SETD2Δ+EV 
samples, regardless of whether signal is enriched above input levels in SETD2 wildtype cells (Figure 
4.13C). Overall, this supports the role of SETD2 as a non-redundant H3K36 trimethyltransferase in human 
cells.  
Figure 4.12: RPKM and methylation levels are positively correlated. Left: boxplots showing methylation 
signal for genes separated by gene RPKM into quartiles. Right: boxplots showing RPKM for genes 
separated by gene methylation signal into quartiles. 
A B 
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4.2.5 Expression of R1625C SET domain mutant fails to restore trimethylation to H3K36 across the 
genome  
As SETD2Δ cells lack H3K36me genome-wide and the R1625C mutant was previously shown to 
be catalytically inactive (Chapter 2, [152]), we examined H3K36me3 levels across the genome in SETD2Δ 
cells stably expressing the R1625C mutant. We hypothesized that there would be little change observed 
between these samples and SETD2Δ samples. Indeed, examining genes shows little to no signal present 
in the SETD2Δ+R1625C sample (Figure 4.14A). Across genomic features, there are few features which  
Figure 4.13: SETD2 loss results in loss of H3K36me3 across the genome. A) Metagene signal of 
SETD2Δ+EV. Average signal (line) for SETD2Δ+EV samples 1000 bp upstream of the TSS, from TSS to 
TTS, and 1000bp downstream of the TTS. Dotted lines represent TSS (left) and TTS (right). B) Boxplots 
for average signal at each feature. Signal was calculated by dividing H3K36me3 normalized values per 
feature by the matched input, averaging replicate values, then log2 transformed for plotting. Values greater 
than 0 (dotted line) are enriched over input. C) Signal at coding exons comparing data from Figure 4.10 
and 4.13B. Color indicates density of points at the location, range from blue (low density) to red (high 
density). 
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Figure 4.14: SET domain mutation shows little to no signal across genomic features. A) Metagene signal 
of SETD2Δ+R1625C samples. Average signal (line) for SETD2Δ samples 1000 bp upstream of the TSS, 
from TSS to TTS, and 1000bp downstream of the TTS. Dotted lines represent TSS (left) and TTS (right). 
Line represents the average signal for all genes, averaged across replicates. Shading represents standard 
deviation between replicates B) Boxplots for average signal at each feature. Signal was calculated by 
dividing H3K36me3 normalized values per feature by the matched input, averaging replicate values, then 
log2 transformed for plotting. Values greater than 0 (dotted line) are enriched over input. 
A 
B 
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display signal levels greater than input, similar to what was seen in SETD2Δ samples (Figure 4.14B). This 
data supports the characterization of the R1625C mutant as catalytically inactive.  
4.2.6 H3K36me3 positive and H3K36me3 negative samples are distinct populations 
As SETD2Δ+EV and SETD2Δ+R1625C cells have been shown to be lack H3K36me3, we explored 
the differences between these H3K36me3 negative cells and the H3K36me3 positive cells. First, principal 
component analysis was conducted on the immunoprecipitation samples and the matched inputs. The first 
component correlates with H3K36me3 status, as the positive samples (SETD2 wildtype, SETD2Δ+tSETD2, 
SETD2Δ+R2510H, SETD2Δ+T2457*) span PC1 (Figure 4.15A). The H3K36me3 negative samples cluster 
with the input samples in PC1. 
The inputs were removed from analysis, and the principal component analysis was repeated. PC1 
again correlates with H3K36me3 status (Figure 4.15B). Each sample type clusters most closely with its 
replicates, suggesting some variation between backgrounds. The exception to this trend is SETD2Δ+EV 
and SETD2Δ+R1625C, which cluster with each other, suggesting high levels of similarity between these 
samples. PC2 in this analysis separates the 786O+EV samples from all others, which may indicate some 
variation based on the SETD2Δ background.  
  
Figure 4.15: Principal Component Analysis separates samples based on H3K36me3 status. A) PCA of input 
and IP samples. Input samples shown in black, IP in cyan. Shape denotes sample type. B) PCA of IP 
samples only. Color denotes sample type.  
A B 
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For further examination of the differences between H3K36me3 positive and negative samples, we 
determined the average signal in 500 base pair windows across the genome, and used DESeq2 [141] to 
cluster this data. We found that H3K36me3 positive and H3K36me3 negative samples form two distinct 
clusters (Figure 4.16A).  This data also shows 786O+EV and SETD2Δ+tSETD2 samples clustering more 
closely together than to SRI altered samples, though the sample distances are similar. An additional 
clustering algorithm, ConsensusClusterPlus [162], generated a similar result (Figure 4.16B). In addition to 
clustering results, conducting multiple unpaired t-tests between samples using 500 base pair windows and 
controlling for false discovery rate (α<0.05) using the Benjamini-Hochberg method [163] allows 
determination of the number of windows which reject the null hypothesis (that there is no difference between 
samples). The comparisons were made pairwise between samples. The number of significant windows can 
be used to generate a dendogram. This analysis shows that SETD2Δ+EV and SETD2Δ+R1625C separate 
from the H3K36me3 positive, and have large numbers of 500bp windows which are significantly different 
from the other samples (Figure 4.16C). Based on these analyses, SETD2Δ+EV and SETD2Δ+R1625C 
appear to be fundamentally distinct from the other H3K36me3 positive samples.  
4.2.7 SRI altered tSETD2 shows few differences to wildtype SETD2 
As SETD2Δ cells lack H3K36me3, comparisons between tSETD2, R2510H and T2457* samples 
with wildtype will be based entirely on the function of the stably expressed construct. As with the 786O+EV 
samples, the signal at genes was examined using a metagene plot. SETD2Δ+tSETD2, SETD2Δ+R2510H, 
and SETD2Δ+T2457* all restore H3K36me3 in a similar distribution to wildtype (Figure 4.17). Additionally, 
examination of signal at specific genomic features reveals a similar pattern of enrichment to that seen in 
786O+EV samples (Figure 4.18). Coding exons show the higher level of enrichment over input in all 
H3K36me3 positive samples, while intergenic regions and promoters show very little enrichment. This 
suggests that SRI domain alteration through mutation or deletion do not drastically alter the overall 
positioning of H3K36me3 across the genome.  
To compare signal at specific genomic regions, the Benjamini-Hochberg method was used again. 
As before, a dendogram was created for each region. At all regions examined, SETD2Δ+EV and 
SETD2Δ+R1625C fell on one arm of the dendogram (Figure 4.19), supporting results described above. 
Also as above, H3K36me3 positive samples consistently group together. 786O+EV, SETD2Δ+R2510H and  
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Figure 4.16: H3K36me3 positive and H3K36me3 negative samples separate based on clustering of 500bp 
windows. A) Cluster generated using DESeq2 analysis of 500bp windows B) Cluster generated using 
ConsensusClusterPlus analysis of 500bp windows. C) Dendogram created based on number of 500bp 
windows which reject the null hypothesis when compared to 786O+EV in the Benjamini-Hochberg method. 
Y-axis represents the number of regions between samples.    
A 
B C 
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Figure 4.17: tSETD2, R2510H, and T2457* restore H3K36me3 to genes in a similar pattern to wildtype 
SETD2. Top: SETD2Δ+tSETD2. Middle: SETD2Δ+R2510H. Bottom: SETD2Δ+T2457*. Metagene signal 
of SETD2Δ+R1625C samples. Average signal (line) for 786O+EV samples 1000 bp upstream of the TSS, 
from TSS to TTS, and 1000bp downstream of the TTS. Dotted lines represent TSS (left) and TTS (right). 
Line represents the average signal for all genes, averaged across replicates. Shading represents standard 
deviation between replicate. 
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Figure 4.18: Coding exons show highest enrichment level across saomples. Boxplots for average signal at 
each feature. Signal was calculated by dividing H3K36me3 normalized values per feature by the matched 
input, averaging replicate values, then log2 transformed for plotting. Values greater than 0 (dotted line) are 
enriched over input. Top: SETD2Δ+tSETD2. Middle: SETD2Δ+R2510H. Bottom: SETD2Δ+T2457*  
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SETD2Δ+T2457* show very little differences at any of the genomic features. As coding exons are the most 
enriched feature of wildtype samples, these were examined more in depth. The number of coding exons 
which reject the null hypothesis varies between samples. Compared to 786O+EV, less than 20 exons reject 
the null hypothesis for both SETD2Δ+R2510H and SETD2Δ+T2457* (Table 4.1). This is in stark contrast 
to the ~90,000 exons which reject the null hypothesis for 786O+EV compared to SETD2Δ+EV and 
SETD2Δ+R1625C. Interestingly, comparing 786O+EV and SETD2Δ+tSETD2 shows an intermediate 
phenotype, with ~24,000 exons that reject the null hypothesis. Overall, these comparisons suggest that 
there are very few differences between SRI altered tSETD2 and wildtype SETD2 in terms of H3K36me3 
deposition.  
Figure 4.19: Benjamini-Hochberg method identifies few differential regions between H3K36me3 positive 
samples. Dendogram created based on number of the given region which reject the null hypothesis when 
compared to 786O+EV in the Benjamini-Hochberg method. Dendograms were created for each examined 
genomic feature. X-axis represents the number of significant regions between samples.   
Number of Regions (*10^5) Number of Regions (*10^5) Number of Regions
Number of Regions (*10^5) Number of Regions Number of Regions
Table 4.1: SRI altered tSETD2 resembles wildtype SETD2 at coding exons. Number of Coding Exons which 
reject the null hypothesis of no difference between the row name and column name using the Benjamini-
Hochberg method. 
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4.2.8 T2457* samples have an altered H3K36me3 pattern at the TSS 
As the metagene shows a rapid increase from the TSS into the gene, we examined H3K36me3 
signal near the TSS. In 786O+EV samples, H3K36me3 increases from the TSS into the gene, similar to 
the result seen in the metagene plot (Figure 4.20A). We next examined the role gene expression plays on 
this phenotype. Genes were separated by RPKM into quartiles and H3K36me3 methylation signal at the 
TSS was plotted for the first and fourth quartile of gene expression (Figure 4.20B). Genes in the first quartile 
of gene expression showed a similar, if diminished, pattern to that seen in all genes, with signal increasing 
from the TSS into the gene. Genes in the fourth quartile showed a large increase in overall signal level, 
indicating again the link between H3K36me3 levels and gene expression.  
As there is a clear pattern for H3K36me3 signal at the TSS, the signal in the other H3K36me3 
positive samples was examined. SETD2Δ+tSETD2 samples showed diminished signal, but the same 
Figure 4.20: H3K36me3 signal increases from the TSS into the gene and correlates with gene expression. 
A) H3K36me3 signal at all genes B) H3K36me3 signal for genes in the first and fourth quartile of expression 
by RPKM. Average signal (line) for 786O+EV samples 1500 bp upstream of the TSS and 1500bp 
downstream of the TSS. Line represents the average signal for all genes, averaged across replicates. 
Shading represents standard deviation between replicate 
A 
B 
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overall pattern as 786O+EV (Figure 4.21A). SETD2Δ+R2510H samples had higher levels of variation, but 
again showed the same general pattern as 786O+EV. An interesting phenomenon was observed in the 
SETD2Δ+T2457*. Rather than a smooth transition from the TSS into the gene, there is an increase in signal 
approximately 500bp downstream of the TSS (Figure 4.21B). This point of inflection is present regardless 
of gene expression levels (Figure 4.21C).  
To further explore this phenotype, we examined individual genes which displayed the point of 
infection in signal. These genes were defined in two ways. First, a subtraction model was used. This model 
subtracts the signal of SETD2Δ+tSETD2 from SETD2Δ+T2457* signal to find genes in which: a) had a 
Poisson peak present in the SETD2Δ+T2457* signal, b) subtraction signal which exceeded a threshold of 
α = 10E-5 (positive or negative) and c) have a region of positive threshold-exceeding subtraction signal 
upstream of the region of negative threshold-exceeding subtraction signal. This method identified 519 
genes. The second method used was a principal component analysis. When examining the signal for 
SETD2Δ+T2457* samples at the TSS, the signal can be broken into principal components using singular-
value decomposition. The first component (PC1) for SETD2Δ+T2457* and SETD2Δ+tSETD2 is the same, 
and represents the signal increase from the TSS into the gene (Figure 4.22). The second component (PC2) 
identifies the peak that can be seen as the major signal. Those genes which had PC2 values above the 
95th percentile were selected, which created a final list of 170 genes. The genes used for both analyses 
were those in the top quartile of gene expression by RPKM. The intersection between these two very 
stringent methods resulted in a final list of 11 genes.  
These genes were examined in the UCSC Genome Browser [164], and the upstream bias of signal 
is stark (Figure 4.23). All genes showed increased signal immediately at the TSS in SETD2Δ+T2457* 
compared to 786O+EV and SETD2Δ+tSETD2. Surprisingly, the upstream bias is also found in the 
SETD2Δ+R2510H sample. The SETD2Δ+T2457* and SETD2Δ+R2510H most closely resemble each other 
at these genes, suggesting this phenotype is due to the lost interaction with RNAPII.  
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Figure 4.21: SETD2Δ+T2457* signal at the TSS is altered from 786O+EV signal. Average signal (line) for 
samples 1500 bp upstream of the TSS and 1500bp downstream of the TSS. Line represents the average 
signal for all genes, averaged across replicates. Shading represents standard deviation between replicate 
A) H3K36me3 signal at all genes for 786O+EV, SETD2Δ+tSETD2 and SETD2Δ+R2510H samples. B) 
H3K36me3 signal for SETD2Δ+T2457* samples with dotted line representing 786O+EV average signal C) 
H3K36me3 signal for genes in the first and fourth quartile of expression by RPKM.  
A 
B 
C 
77 
 
  
Figure 4.22: Principal component analysis show presence of inflection point in SETD2Δ+T2457*. Signal at 
the TSS for SETD2Δ+tSETD2, SETD2Δ+T2457* and SETD2Δ+EV. Signal is plotted per replicate. Top: 
H3K36me3 signal at genes in the top quartile of gene expression. Middle: principal component one of the 
signal from top. Bottom: principal component two of signal from top. Black vertical lines represent region 
used to identify genes with point of inflection in SETD2Δ+T2457* samples.  
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Figure 4.23: H3K36me3 signal at individual genes shows upstream bias of SRI altered samples. 
Sequencing tracks obtained from the UCSC genome browser [164]. Top: H3K36me3 signal at the LDHA 
locus. Y-axis is signal levels, x-axis is genomic position. LDHA starts in center and proceeds to the right. 
Bottom: H3K36me3 signal at the SNHG1 locus. Y-axis is signal levels, x-axis is genomic position. SNHG1 
starts in center and proceeds to the left. LDHA and SNHG1 are two representative genes of this 
phenomenon.  
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4.3 Discussion  
In an effort to understand the effect of mutation on H3K36me3 positioning, we conducted ChIP-Rx 
for this mark in a variety of SETD2 mutant backgrounds. In this chapter, we demonstrated complete loss of 
H3K36me3 in SETD2Δ cells, as well as verified the catalytic inactivation of SETD2 by the R1625C mutation. 
This is in contrast to previously published work which showed that loss of SETD2 through zinc-finger 
nuclease inactivation results in gains in H3K36me3 in intergenic regions [94]. This study was also 
conducted in 786O, so genomic background is not the source for the difference. The study, however, did 
not use a spike-in normalization strategy. The H3K36me3 negative samples show substantial increase in 
the percent of reads mapping to Drosophila, which indicates a immunoprecipitation shift to the H3K36me3 
positive Drosophila cells from the H3K36me3 negative human cells, and likely explains the differential 
findings of these two studies. This provides further support for the need to incorporate a normalization 
strategy when conducting sequencing experiments, especially when levels of the mark of interest are 
diminished.  
This chapter also expanded on current knowledge of wildtype SETD2 by examining the coding 
exon preference of H3K36me3. The level of methylation did not correlate with exon length, but overall gene 
methylation did correlate with gene expression. This data enforces the link between H3K36me3 and 
transcription by suggesting gene expression is the key determinant of H3K36me3 levels. Additional work 
examining the role of nucleosome occupancy in H3K36me3 enrichment in coding exons will further explore 
this phenotype, as this has been suggested as a source of H3K36me3 enrichment in exons [63].  
The data from SETD2Δ+tSETD2 samples suggest that the N-terminus is not necessary for faithful 
H3K36me3 placement. This is an intriguing finding, as the N-terminus region is not present in yeast Set2, 
but is present in many of the SETD2 homologs found in other organisms, including P. troglodytes, C. lupus, 
B. taurus, M. musculus, D. rerio, and D. melanogaster. This suggests that the N-terminus was evolutionarily 
selected, and therefore would be predicted to have a role in SETD2 function. Our data suggest that this 
role is not directly invovled in H3K36 trimethylation regulation.  
One facet of SETD2 biology which has made study of this protein difficult is the low levels of 
expression for SETD2 in human cells. This was recently explored, and a region from amino acid 1104-1403 
was shown to harbor a protein degradation signal which was MG132 dependent [165]. In addition, a region 
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from amino acid 504-803 may provide a signal for protein stability.  This suggests the N-terminus is required 
for regulating protein levels, but not for functional activity. tSETD2 begins at amino acid 1323 and thus lacks 
the latter region entirely, and contains less than 100 amino acids of the former region, and this may be why 
visualization of tSETD2 is possible while visualization of SETD2 is difficult. It is possible that the proteasome 
degradation sequence found from amino acid 1104-1403 is still present. Further detailed biochemical 
examination of this region will be required to determine the final protein sequence responsible.  
Interestingly, tSETD2 often showed lower levels of H3K36me3 compared to 786O+EV. This could 
be due to the low levels of expression of tSETD2 compared to the other mutants. This may suggest that 
protein levels are very tightly regulated, and do contribute to over H3K36me3 levels. However, tSETD2 is 
expressed at levels most similar to wildtype SETD2. An additional argument against the low expression of 
tSETD2 contributing to low H3K36me3 signal is the high levels of the R2510H and T2457* mutant proteins 
do not fundamentally alter the H3K36me3 localization. It is also possible that the low levels of tSETD2 are 
due to a lower percentage of GFP positive cells. If a smaller percentage of cells are positive for GFP (and 
by proxy tSETD2), this would shift the normalization strategy and impact downstream analyses. tSETD2 
did have a significant difference between input percent Drosophila and sample percent Drosophila, which 
would suggest a shift from human cells to Drosophila cells in this sample. This shift is the most likely source 
of decreased signal in these samples.   
We have shown that mutation or deletion of the SRI domain disrupts the interaction between 
tSETD2 and RNAPII. Given this, the finding that SETD2Δ+R2510H and SETD2Δ+T2457* samples have 
very little of variation from 786O+EV was surprising. We had hypothesized that the interaction with RNAPII 
would be crucial to proper H3K36me3 placement. Instead, coding exons still showed the highest level of 
enrichment. Additionally, the number of coding exons which were significantly different between SRI altered 
tSETD2 and wildtype SETD2 was in the single digits when compared to 786O+EV. It is possible that there 
are differences due to SRI domain loss in regions of the genome which were not examined in this 
manuscript, however, the most prominent features of H3K36me3 are unaltered. This leaves the question 
of the role of the SRI domain mutation in ccRCC somewhat open.  
Evidence has shown the SRI domain interacts with the hyperphosphorylated form for RNAPII [5]. 
Hyperphosphorylated RNAPII is phosphorylated on serine-2 and serine-5 of the C-terminal repeat domain, 
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and is the elongating form of polymerase (reviewed in [166]). The SRI domain has been shown to have no 
affinity for RNAPII when it is only phosphorylated at serine-2 or serine-5 [5].  It is possible that SETD2 is 
interacting with RNAPII at an undetectable levels in vitro through a non-SRI mechanism. Were this the 
case, we would expect the interaction to be equivalent between hyperphosphorylated and 
unphosphorylated, and that the SRI altered forms of tSETD2 would have a skewed interaction for the 
unphosphorylated. As unphosphorylated RNAPII is found at promoters and early in the gene, the 5’ bias of 
SETD2Δ+R2510H and SETD2Δ+T2457* would support this possibility. The HA-RNAPII co-
immunoprecipitation in this study was done using an antibody which recognizes both the phosphorylated 
and unphosphorylated forms of RNAPII. Studies using antibodies which recognize particular 
phosphorylation states could help parse this interaction.  
Overall, this data supports that of Chapter 2, showing total loss of H3K36me3 with TALEN 
inactivation of SETD2, as well as loss of catalytic activity by the R1625C mutant. Furthermore,  it defines a 
separation of function for the SET and SRI domains of SETD2. Future work will explore the role of the SRI 
domain in additional processes to determine how a ccRCC-associated mutation in SETD2 that does not 
alter H3K36me3 placement contributes to cancer development. 
4.4 Methods 
4.4.1 Stable expression of tSETD2 and mutants 
To generate stably expressing cells, 786O parental, 786O SETD2Δ, HKC parental and HKC 
SETD2Δ cells were transduced with empty vector (EV), tSETD2, R1625C, R2510H, or T2457* virus. After 
transduction, cells were sorted by GFP status into 96 well plates, 5 cells per well. After two weeks, the cells 
were checked for proliferation and GFP levels. Those wells which had proliferated and were 100% GFP 
positive were combined (3-5 wells) into a 24 well plate. This population was expanded and sorted again for 
the highest intensity GFP positive cells.  
4.4.2 Flow Cytometry 
Cells were grown on 10cm2 plates to near confluency, isolated and pelleted. The pellets were 
washed with PBS, and stained with propidium iodide (PI) as a live-dead discriminator. Flow cytometry for 
PI and GFP was conducted on the Becton Dickinson LSRFortessa. Plots were generated using the Flowing 
Software version 2.5.1.  
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4.4.3 Protein extraction 
Histones were extracted for histone western blots using an acid extraction protocol. Briefly, cells 
were pelleted and washed in cold PBS, then resuspended in TEB lysis buffer (PBS containing 0.5% Triton 
X 100 (v/v), 2mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3). Cells were lysed by nutation 
for 10 minutes at 4°C. Lysate was pelleted, washed, and overnight acid extracted in 0.2N HCl. RIPA extracts 
were used for HA and GFP blots. RIPA (25mM Tris, 150mM NaCl, 0.1% SDS, 0.5% Na-deoxycholate, 1% 
Triton X/NP-40) was added to cold cell pellets, and incubated on ice 10 minutes. Lysates were centrifuged 
at high speed and supernatant was retained. For chromatin fractionation cell pellets were snap frozen in a 
dry-ice ethanol bath. Pellets thawed on ice, then were resuspended in CSK buffer (10mM Pipes, pH 7 with 
NaOH, 300mM sucrose, 100mM NaCl, 3mM MgCl2, 0.1% Triton-X 100, 1x protease inhibitors, 1mM NaF). 
Sample was centrifuged, and supernatant retained as the soluble fraction. Pellet was washed in CSK, and 
resuspended in 1mL CSK as the chromatin fraction, which was used for immunoprecipitation.   
4.4.4 Western blots 
For histone western blots, 4-15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels (Bio-Rad) were 
used. For HA and RNAPII blots, Any kD™ Mini-PROTEAN® TGX Stain-Free™ Protein Gels (Bio-Rad) 
were used. Antibodies used were anti-H3 (abcam ab10799), anti-H3K36me3 (abcam ab9050), anti-HA 
(Biolegend 901502), anti-RNA Pol II (Active Motif 39097), anti-tubulin (Sigma T9026), and anti-GFP (Cell 
Signaling Technology #2555). Secondary antibodies were LI-COR IRDye® 800CW Goat anti-Mouse, LI-
COR IRDye® 680CW Goat anti-Mouse, LI-COR IRDye® 800CW Goat anti-Rabbit, LI-COR IRDye® 680CW 
Goat anti-Rabbit. Transfers were onto a nitrocellulose membrane, and were either 100V for 1 hour for 
histone blots or 30V for 12 hours for HA and RNAPII blots. 5% BSA in PBS was used for blocking, and 
antibodies were diluted in 5% BSA in PBS-T.   
4.4.5 Co-immunoprecipitation  
293T cells were transiently transfected using the TransIT®-LT1 Transfection Reagent with 10ug of 
empty vector, tSETD2, R2510H or T2457* plasmid. HKC stable expression cells were generated as 
described above. Cell pellets were resuspended in high salt IP buffer (50mM Tris pH 8, 300mM NaCl, 10% 
Glycerol, 1% NP-40, 20mM NaF, 10mM Sodium Pyrophosphate, 10mM Sodium Orthovanadate, 1x 
protease inhibitors), lysed by pipetting, and nutated at 4°C 30 minutes. The sample was spun and 
83 
 
transferred to a new tube, where it was diluted 1:1 with no salt IP buffer (50mM Tris pH 8, 10% Glycerol, 
1% NP-40, 20mM NaF, 10mM Sodium Pyrophosphate, 10mM Sodium Orthovanadate, 1x protease 
inhibitors), nutated at 4°C 30 minutes, then 2µg anti-HA (Biolegend 901502) was added and nutated 
overnight at 4°C. Washed Bio-Rad Protein G Surebeads (Bio-Rad 1614023) were added to the sample and 
nutated 2 hours at 4°C.  The supernatant was discarded and the beads were wash 4x with mid-salt IP buffer 
(50mM Tris pH 8, 150mM NaCl 10% Glycerol, 1% NP-40, 20mM NaF, 10mM Sodium Pyrophosphate, 
10mM Sodium Orthovanadate, 1x protease inhibitors). The sample was eluted by addition of 40uL of 
Laemmli buffer (63mM Tris-HCl, 10% Glycerol, 2% SDS, pH 6.8) and incubation at 70°C for 10 minutes. 
For chromatin fraction immunoprecipitation, fraction was generated as described above, and incubated 
overnight with 2µg anti-H3K36me3. Immunoprecipitation proceeded as above, with wash in CSK rather 
than mid-salt buffer.  
4.4.6 ChIP-Rx 
Cells used included 786O+EV, SETD2Δ+EV, SETD2Δ+tSETD2, SETD2Δ+R1625C, 
SETD2Δ+R2510H and SETD2Δ+T2457*. Two confluent 15cm2 plates per cell type were fixed by addition 
of formaldehyde to a final concentration of 1%. Formaldehyde was inactivated with 125mM glycine, then 
cells were washed, collected by scrapping and pelleted. The pellets were resuspended in hypotonic 
homogenization buffer (10mM Tris pH 7.4, 15mM NaCl, 60mM KCl, 1mM EDTA, 0.1% NP-40, 5% sucrose, 
1x protease inhibitors (Roche)) and dounced with 10 strokes. A sucrose pad (10mM Tris pH 7.4, 15mM 
NaCl, 60mM KCl, 10% sucrose, 1x protease inhibitors) was added to the bottom of samples, and samples 
were centrifuged. The supernatant was removed, and isolated nuclei were stored at -80.  
Frozen nuclei were thawed on ice, resuspended in ChIPs buffer (10mM Tris pH 7.4, 100mM NaCl, 
60mM KCl, 1mM EDTA, 0.1% NP-40, 1x protease inhibitors, 0.05% SDS), and sonicated to an average 
fragment size of 500 base pairs. Anti-H3K36me3 (abcam ab9050, Lot GR233723-2) antibody was added 
to Bio-Rad Protein A Surebeads (Bio-Rad 1614013), rotated for 10 minutes, washed, then 400uL of 
sonicated sample was added to the beads. After 1 hour of rotation at room temperature, the supernatant 
was discarded and the beads were wash 4x with PBS-T. The sample was eluted by addition of 40uL of 
Laemmli buffer and incubation at 70°C for 10 minutes. Elution was treated with RNAse-A and Proteinase 
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K, left at 65°C overnight, and then cleaned on Zymo ChIP DNA Clean & Concentrator columns (Zymo 
D5201).  
4.4.7 Library preparation 
Sequencing libraries for ChIP DNA all followed the standard Illumina sequencing protocol. 10ng of 
DNA was used as starting material. Libraries were generated for both the ChIP DNA and the DNA from the 
ChIP input. DNA was blunted, purified using Ampure XP beads, A-tailed, adapter ligated, purified using 
Ampure beads two additional times, before PCR amplification (15 cycles) and one additional purification. 
Final libraries were submitted as a pool to the UNC High Throughput Sequencing Facility (HTSF) for 
sequencing. ChIP-seq utilized 9 lanes of single-end 50bp reads.  
4.4.8 Sequencing Pipeline  
Data was obtained from UNC HTSF, then processed by the in-house sequencing pipeline. This 
pipeline processed the files to remove adapters using TagDust [145].  Paired-end sequences were 
synchronized to each other, then aligned to the genome using Bowtie [146].  The bowtie output files were 
convered to BAM files using samtools [147], then filtered for properly mapped reads. These files were used 
to generate downstream files for additional analyses. 
Data was normalized to drosophila DNA content. The number of reads mapping to the drosophila 
genome and the number of reads mapping to the human genome was determine, which those ambiguously 
mapped to both removed.  The normalization constant was determined as α=1/count of reads (in millions) 
aligning to the Drosophila genome, and is determined for each file. During wiggle file generation, the base 
count is multiplied by this normalization constant. Wiggle files have read extension to 500 base pair from 
the 50bp reads from the sequencer, as this was the average fragment length as determined by bioanalyzer 
tracings (data not shown).  
4.4.9 Data analysis 
Metagene analysis was conducted using CEAS [160]. CEAS generates the signal across each 
gene, and outputs an average value across a 3000 range. Genes which are smaller than 3000 will be 
expanded to fill this range, while genes larger than 300 will be compressed. The CEAS computed value 
was read into R [167], where the average and standard deviation for the 3 sample replicates was determine. 
The average value was plotted as a line, with shaded standard deviation added.  
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Signal enrichment was calculated using Zinba [149] and R. Genomic regions were downloaded 
from the UCSC Table browser [150]. Promoters were defined as 1kb upstream of the TSS and downloaded 
as such. Intergenic regions were generated by subtracting genes and promoters from the total genome. All 
other regions were defined through the UCSC download tool. Once files were downloaded, they were 
converted to Zinba format. Wiggle files for each sample and input were used to determine the signal at 
every base pair of the genomic region. The average signal per region was determined using an in-house 
perl script. The average signal per region was then read into R, and the sample signal was divided by the 
input singal, then this was averaged between replicates. The final signal was then log2 transformed, and 
plotted as boxplots using R. Zinba was also used to find signal at the TSS.  
 Density plots were also generated in R using the densCols function. densCols determines the 
density at each point. The ColorRampPalette function can then be used to assign a color to this density, 
with 256 color splits. This density can then be plotted as a scatterplot.  
Principal component analysis was also completed in R using the prcomp function. Samples and 
inputs were divided into 500 base pair windows of average signal per window. A matrix of these files was 
generated, which was then used by the prcomp function, with center and scale set as true. Plots are of the 
first principal component versus the second.  
Dendogram analysis was competed using the Benjamini-Hochberg method [163]. The average 
signal per region files described above were used as an input. Unpaired t-tests between samples were 
conducted for each region, and the false discovery rate was set at α<0.05. The number of regions which 
reject the null hypothesis that there is no difference between samples was output, and used to generate a 
dendogram. The axis of this dendogram represents the number of regions.   
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CHAPTER 5: Conclusions and Discussion
 5.1 Overall Summary 
The focus of this work has been on SETD2 loss and mutation, specifically in the context of clear 
cell renal cell carcinoma. In Chapter 1, the overall role of SETD2 in the cell is discussed. SETD2 is a non-
redundant histone H3 lysine 36 methyltransferase [1], as we have verified by ChIP-seq in Chapter 4. It has 
been shown to be involved in transcription [61,62,64], RNA processing [64,70–72], and DNA damage repair 
[83,84,86]. The role of SETD2 mutation in cancer is still largely unexplored. This work attempts to fill in the 
knowledge gap in ccRCC development. 
We selected two ccRCC-associated mutations for initial study. The first chosen mutation, R1625C, 
is found in the SET domain. The second, R2510H, occurs in the SRI domain. We inactivated SETD2 in 
human cells using TAL effector nucleases and introduced a truncated but functional wildtype SETD2 
(tSETD2), as well as the two mutants in the tSETD2 background into these cells. We found that SETD2 
inactivation resulted in global loss of H3K36me3, which was not rescued by expression of the R1625C 
mutant. Expression of tSETD2 and R2510H restored H3K36me3 globally. We show that loss of catalytic 
activity in the R1625C mutant line was due to reduced substrate-binding capacity of this variant.  
To further study ccRCC-associated mutations, we took advantage of the similarities between 
human SETD2 and the yeast ortholog of SETD2, Set2. Set2 has all of the functional domains found in 
SETD2, and is responsible for all levels of H3K36 methylation in yeast. We generated the ccRCC-
associated mutations in Set2, as well as an additional H199L mutation. We found that the R2510H yeast 
equivalent mutation, K663L, did not alter H3K36me3 levels, while the R1625C equivalent, R195C, 
abolished H3K36me3 abilities of Set2 without altering H3K36me2 or H3K36me1. The H199L mutation 
resulted in loss of both H3K36me3 and H3K36me2. With this series of mutants, we were able to examine 
the effect of mutation on known Set2-associated phenotypes. We found that cryptic initiation, phleomycin 
sensitivity and 6-AU treatment resistance were all dependent on dimethylation rather than trimethylation. 
Based on this result, we examined similar features in human cells. We found that γH2A.X levels after DNA 
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damage were higher in H3K36me3 deficient samples, but that this did not alter survival after DNA damage, 
in agreement with the yeast results.  
We further explored the effects of SETD2 loss by examining SETD2Δ cells for changes in 
transcription and chromatin organization. Previous studies had shown widespread changes in chromatin 
accessibility in SETD2 mutant ccRCC tumors [17]. We hypothesized that these changes were due to 
alterations in nucleosome positioning, and chose to study this using MNase-seq. We did not observe 
widespread changes in nucleosome positioning at the TSS or internal exons, though we did show increased 
gene expression correlated with increased MNase signal at the TSS. In order to examine changes in 
chromatin accessibility more broadly, we conducted FAIRE-seq in the SETD2 wildtype and SETD2Δ cells. 
We found approximately 8000 regions of altered accessibility, with the majority showing increased 
accessibility in the SETD2Δ cells. This was in agreement with the results seen in tumors.  We then 
examined the properties of the nucleosomes found in regions of increased accessibility, and found 
nucleosomes in these regions show decreased positional conservation, increased occupancy, but fewer 
overall nucleosomes. This suggests that there is wider variation in nucleosome positioning in regions of 
increased chromatin accessibility in SETD2Δ cells.  
Studies of SETD2 mutant ccRCC tumors also showed widespread alterations in RNA processing. 
Based on this, we examined RNA in the SETD2Δ cells using RNA-seq. Surprisingly, in both the 786O and 
HKC cellular background we found very few genes that showed alterations in gene expression. Those that 
were significantly different often showed small changes. Additionally, the differential genes found in 786O 
did not overlap those found in HKC. Examining the SETD2Δ replicates showed substantial variation 
between replicates, which likely accounts for the low number of significantly different genes. Examining 
RNA splicing showed similar levels of intron retention between wildtype and knockout samples in both 786O 
and HKC samples. Overall, changes in RNA were found at low levels and were not consistent between 
replicates.  
We next examined the effect of SETD2 mutation on H3K36me3 localization using a spike-in 
normalization strategy. SETD2 loss and the R1625C SET domain mutation result in complete loss of 
H3K36me3 genome-wide. We examined H3K36me3 localization in the 786O parental cells and showed 
signal increases along the length of the gene. Coding exons show the highest levels of enrichment for 
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H3K36me3, while non-genic regions show the lowest levels. H3K36me3 levels correlated with gene 
expression but not exon length. Clustering shows that H3K36me3 positive samples consistently cluster 
together, and have similar distances between them. SETD2Δ+tSETD2, SETD2Δ+R2510H, and 
SETD2Δ+T2457* samples all show a pattern similar to wildtype across genes and have high levels of 
H3K36me3 enrichment at coding exons. 
Further examination of signal at the TSS showed that the SETD2Δ+T2457* had an increased level 
of signal early after the TSS. This was consistent regardless of the gene expression level. Examining 
specific loci showed that there was a shift in H3K36me3 levels towards the TSS. Interestingly, this shift was 
also seen in the SETD2Δ+R2510H when specific genes were examined. This suggests that the increase 
in signal near the TSS is due to lost interaction with the hyperphosphorylated RNAPII.  
This work has expanded on the current understanding of SETD2 biology. The inactivation of 
catalytic activity by the R1625C mutation supports the role of H3K6me3 loss in ccRCC development. The 
fact that the SRI domain does not alter H3K36me3 levels or localization is a novel finding, and brings into 
question the relationship between SETD2 and RNAPII. This separation of function between domains will 
be of key importance when designing therapeutics which target SETD2 mutation in ccRCC. Future studies 
will expand on this novel finding by exploring the relationship between the SRI domain and ccRCC 
development.  
5.2 Transcription and Chromatin 
One the surprises of this work was the relatively low amount of variation observed between SETD2 
wildtype and SETD2Δ cells in chromatin and transcription assays. Given the substantial amount of 
published work that showed a role for H3K36me3 in transcription and RNA processing, we predicted that 
loss of SETD2 would have a large effect on RNA abundance and splicing. Ultimately, this is not what was 
observed. What was notable was that there were large numbers of genes which showed high levels of 
variation, but these genes were not consistent between samples. This opens an intriguing possibility. As 
SETD2 and H3K36me3 have been implicated in DNA damage repair, it is possible that the cells used for 
these studies have diverged during growth and passage. The longer the cells were grown, the further the 
SETD2Δ replicates diverged from each other. As a result, their gene expression profiles would likely change 
as well. The process by which the SETD2Δ replicates were generated started at a single cells stage, which 
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then grew into a population of cells over the course of many weeks. Within this population it is also possible 
that subpopulations may have emerged if DNA damage occurred and was poorly repaired.  
The work from ccRCC tumors would support this as a possibility. The ccRCC TCGA data analysis 
did not identify a consistent gene expression signature specific to SETD2 mutant tumors [18]. One way to 
test for this would be to repeat RNA sequencing with a technical replicate rather than biological replicates. 
If the number of statistically significant genes drastically increases and there is still little overlap between 
different SETD2Δ samples, there is likely not a consistent pattern of gene expression related to SETD2 
loss. This work provides support for this hypothesis. Future studies can expand on this finding by showing 
consistency between technical replicates, as well as showing changes in gene expression which occur over 
time. Inducible loss of SETD2 would allow examination of RNA immediately after SETD2 loss, rather than 
after several cell divisions. This would allow comparison between acute and chronic SETD2 loss, which 
would provide more insight into early ccRCC development after SETD2 mutation.  
We also examined the effect of SETD2 loss on chromatin organization. Again, we were surprised 
that changes in nucleosome positioning were not more widespread. Evidence from SETD2 mutant tumors 
suggested that altered chromatin organization at exons was due to altered nucleosome positioning. We did 
not observe changes in nucleosome positioning at internal exons. We did, however, see changes in 
nucleosome properties at regions with altered chromatin accessibility. Recent studies have shown that 
changes in chromatin accessibility can occur without changes in nucleosome positioning [142]. Studies in 
yeast have shown that H3K36me2 recruits the Rpd3s histone deacetylase complex to genes, resulting in 
decreased acetylation [112]. Additionally, H3K36me3 in yeast recruits the NuA3b acetyltransferase 
complex through the PWWP domain of Pdp3 [168].  This suggests that loss of H3K36me3 could result in 
decreased acetylation. It is also possible H3K36me3 may be recruiting additional chromatin modifiers to 
genes, altering the chromatin landscape. To test this, the acetylation state of individual and neighboring 
nucleosomes could be studied. One method to examine modifications on individual nucleosomes is 
Combinatorial-iChIP. This process identifies modifications which are found on the same nucleosomes using 
a dual barcoded ChIP re-ChIP method [169]. This would allow examination of various acetyl states on 
H3K36me3 marked nucleosomes. Marks which are common to these nucleosomes can then be studied in 
the H3K36me3 negative cell lines for changes using ChIP-Rx. Additionally, we could develop a process to 
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study neighboring nucleosomes. This process might use MNase to generate dinucleosomes, which are 
then immunoprecipitated for the mark of interest (i.e. H3K36me3). The dinucleosomes could then be 
cleaved to mononucleosomes, which are then queried for various modifications. This would enable 
examination of the ‘next’ nucleosome’s modification state. In general, understanding the precise state of a 
region of chromatin will provide further insight into the specific processes which are affected by the loss of 
a particular mark. For SETD2 biology, this would provide a comprehensive understanding of how chromatin 
is affected by SETD2 loss in ccRCC.   
5.3 The role of the SRI domain 
The most surprising finding of this work was the relatively normal genomic targeting of H3K36me3 
in SETD2Δ+R2510H and SETD2Δ+T2457* cells. This contradicts the traditional view of SETD2 interacting 
with RNAPII to mark nucleosomes within a gene. We show that both SRI domain mutations disrupt the 
interaction between SETD2 and RNAPII, so this finding indicates that this interaction is not necessary for 
normal H3K36me3 placement. If this is true, the obvious question then becomes “What is the role of the 
SRI domain?”  
The focus of this work has been on the function of SETD2 as a histone methyltransferase. This is 
a logical choice, as until recently H3K36 was the only known target of SETD2. However, recent studies 
have questioned this, and at least one new target has been identified. A recent study (which we were 
involved in as collaborators) showed that SETD2 also targets tubulin for methylation [109]. Loss of this 
tubulin mark leads to mitotic and cytokinetic errors, which likely contributes to genome instability in ccRCC. 
The study examined the effect of ccRCC-associated mutations on tubulin K40me3 levels. R1625C 
expression failed to restore this mark in SETD2Δ 786O cells, which would be expected as it is catalytically 
inactive. Surprisingly, the expression of the R2510H mutant in SETD2Δ also failed to restore tubulin 
K40me3. This suggests that the SRI domain is required for tubulin methylation, and our data suggest it is 
not required for histone methylation. Further exploration of the tubulin methylation will be required to verify 
the role of the SRI domain. If the SRI domain is required, we would observe no tubulin K40me3 with 
expression of the T2457* SRI deletion. In addition, expression of tSETD2 should rescue mitotic defects, 
while expression of R2510H or T2457* will not. This work is currently being examined in our lab and that of 
our collaborators. 
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It is possible that the SRI domain only stabilizes the interaction between the RNAPII elongating 
complex and SETD2 through the interaction with the hyperphosphorylated CTD. The elongating complex 
consists of many proteins, including cleavage and polyadenylation factors (reviewed in [166]). Without the 
stabilization provided by the SRI domain, T2457* may still be capable of interaction with other members of 
this complex.  A comprehensive analysis of the proteins that interact with SETD2 would provide further 
insight into how SRI altered tSETD2 is able to mark genic regions in a similar manner to wildtype, despite 
lost interaction with RNAPII. This could be completed by mass spectrometry or yeast two-hybrid screening 
for protein partners. As more methylation targets and interacting partners for SETD2 are identified, it will 
be crucial to examine the role of the SRI domain in these functions.    
5.4 SETD2 mutation and therapeutics 
ccRCC is one of the ten most common cancers in both men and women in the United States [134]. 
SETD2 is mutation in ccRCC has been associated with decreased overall survival and is a univariate 
predictor of survival [103]. SETD2 mutant tumors are also more likely to present with stage III or higher 
disease [104]. The state at which a tumor is found is a key determinant of survival. Five year survival for 
ccRCC in the United States from 2005-2011 was 92% for localized disease, 65% for regional disease, and 
12% for metastatic disease (reviewed in [170]). The need for better therapeutics in metastatic disease is 
obvious. Recent studies have explored SETD2 loss as a therapeutic target for ccRCC. The Genomics of 
Drug Sensitivity in Cancer database [171] lists 4 compounds which selectively affect SETD2-/- cell lines 
(reviewed in [172]). Of these, two are PI3Kβ inhibitors. One study examined the effects of PI3Kβ inhibition 
in ccRCC cells and found that TGX221 selectively inhibited ccRCC cells with both VHL and SETD2 
mutations [173]. A different study found that WEE1 inhibition in H3K36me3-deficient cells results in RRM2 
reduction, critical dNTP depletion, S-phase arrest, and apoptosis [95].  
One key feature of both these studies is they examine the effect of the compound of interest in the 
context SETD2 and H3K36me3 loss. The work in this dissertation however suggests the H3K36me3 loss 
and SETD2 mutation are not equivalent. Targeting SETD2 loss is effective if the ccRCC tumor has 
mutations which are early inactivating or occur in the SET domain. We have determined, however, that SRI 
domain mutation is fundamentally different from SETD2 loss. There is little to no effect on H3K36me3 in 
SRI mutant cells, thus limiting the therapeutic focus in ccRCC to H3K36me3 loss will not help develop 
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treatments for SRI mutant tumors. Treating SETD2 mutant tumors will thus have to encompass two tasks: 
directing therapies at H3K36me3 loss and targeting SRI domain alteration.  
Therapeutically targeting SRI domain mutations is an unexplored field. As stated above, the SRI 
domain has been implicated in tubulin methylation. It may be possible to treat SRI domain mutants by 
inhibiting mitosis. There are several chemotherapeutics used in clinic to target the mitotic checkpoint, 
including taxanes and vinca alkaloids [174]. A recent study of the Aurora kinase inhibitor VX680/MK-0457 
in ccRCC cells showed inhibition of cell growth in vitro [175]. Aurora kinases are regulators of mitosis, and 
have previously been implicated in tumorigenesis. They are also upregulated in ccRCC compared to normal 
kidney. It is possible that this inhibitor may specifically aid in the treatment of SRI mutant ccRCC, and may 
be less of effective in ccRCC with other types of SETD2 mutation.         
5.5 In conclusion 
SETD2 mutation is a common event in ccRCC that is associated with worse prognosis. 
Understanding of these mutations is critical to developing therapeutics to treat this disease. Mutations in 
SETD2 which are early inactivating or interrupt the catalytic SET domain result in complete loss of 
H3K36me3, while those in the SRI domain have little effect on this mark. These results show the importance 
of studying specific cancer-associated mutations rather than focusing on protein loss. Had we limited our 
work to specifically studying the effect of SETD2 loss, we would have concluded that the role of SETD2 
mutation in ccRCC development was dependent on H3K36me3 loss. By conducting a domain-specific 
analysis, the novel finding that the SRI domain is not required H3K36me3 placement was identified. Future 
work will further explore the role of the SRI domain in cancer development, by investigating the effect on 
tubulin methylation, identifying additional interacting partners, and examining therapeutic opportunities 
specific to this mutation. 
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APPENDIX: A Tale of Two Cancers - Complete genetic analysis of Chromophobe Renal Cell 
Carcinoma contrasts with Clear Cell Renal Cell Carcinoma3
The Cancer Genome Atlas projects in rare tumor types offer unique insights into mechanisms of 
tumorigenesis. The first such project studied Chromophobe Renal Cell Carcinoma, ChRCC [176]. ChRCC 
represents 5% of renal cell carcinoma cases [177], and is associated with a striking aneuploidy pattern 
[178]. Our analysis of 66 cases of non-hereditary ChRCC included whole-exome DNA sequencing for all 
cases, along with whole-genome DNA sequencing in 50 of these cases, and 61 cases with mtDNA 
sequencing by long range PCR. All cases also were studied for copy number analysis, mRNA and miRNA 
sequencing, and CpG DNA methylation.  
Our analyses verified large-scale chromosomal loss that has previously been described, with 86% 
of cases showing loss of one copy of the entire chromosome, for most or all of chromosomes 1, 2, 6, 10, 
13, and 17. Between 12% and 58% of cases also showed entire chromosomal loss for chromosomes 3, 5, 
8, 9, and 21. Chromophobe has also been defined with histological classifications, classic and eosinophilic. 
Of the 47 tumors with classic histology, all showed the characteristic chromosomal loss, while only 10 of 
the 19 eosinophilic cases showed these losses. Additionally, eosinophilic cases showed no chromosomal 
loss, suggesting a degree of genomic heterogeneity as a distinguishing characteristic of ChRCC histology 
classification.  
Whole exome sequencing showed relatively low numbers of somatic mutations, with only 2 
reaching a threshold of being called frequently mutated genes (occurring in >5% of cases). TP53 mutations 
were identified in 21 cases (32%), and PTEN was mutated in 6 cases (9%). With only two common 
mutations, our analyses turned to methylation changes, mitochondrial DNA, and structural changes. 
By comparing methylation patterns between the most common subtype of RCC, clear cell renal cell 
carcinoma (ccRCC), and ChRCC, we were able to identify distinct differences between these two subtypes, 
suggesting a potential difference in cell of origin. To further examine this possibility, we compared RNA seq 
gene expression data from both diseases to an external gene expression data set of normal kidney which 
had been microdissected from various regions of the nephron [179]. ChRCC mRNA expression highly 
                                                     
3This research has been published in Molecular & Cellular Oncology. Fahey CC, Rathmell WK. A tale of 
two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell 
renal cell carcinoma. Mol Cell Oncol. 2015;2: e979686. doi:10.4161/23723556.2014.979686 
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correlated with expression profiles from distal regions of the nephron, while ccRCC mRNA expression 
correlated with expression profiles from the proximal nephron.   These results suggest that molecular 
differences between these subtypes may be defined and influenced by distinct cells of origin. 
Bioenergetic features were prominent in both ccRCC and ChRCC, but in highly divergent patterns. 
In ChRCC, nearly all genes involved in the Krebs cycle showed increased expression when compared to 
normal kidney, as did at least one gene for each complex involved in the electron transport chain (ETC). 
There were also increased mitochondrial genome numbers in ChRCC. Interestingly, mitochondrial related 
genes are strongly repressed in ccRCC, highlighting another important distinction between these two 
subtypes [18]. Additionally, these differences suggest alternate strategies to support tumor growth rather 
than minimizing reliance on oxidative phosphorylation.  
Further mitochondrial analysis revealed a high frequency of somatic mutations in mitochondrial 
genes at various levels of heteroplasmy. 12 tumors had nonsilent mutations, including many frameshift 
mutations. Mitochondrial gene mutations have been described previously [180], but this analysis confirms 
both the high frequency of events, and a close link of these mutations to the eosinophilic subgroup. 
Generally, these mutations were predicted to be inactivating. Specific mutations were identified in MT-ND5, 
an essential member of ETC complex I, including one previously identified cancer-associated mutation 
[181]. Intriguingly, mutations in complex I were not correlated with alterations in expression patterns 
associated with loss of oxidative phosphorylation. This suggests an alternate role for complex I alteration 
in cancer metabolism, or a compensatory mechanism of increased gene expression, that does not reflect 
the same change in metabolic activity. Ultimately, measurements of substrate utilization and dynamic 
metabolic processing will be required to resolve the true metabolic state of these tumors.  
The whole genome analysis identified two novel findings in ChRCC cases. A subset of samples 
displayed kataegis, the occurrence of highly localized substitution mutations (C>T or C>G) [182,183], which 
were localized with regions of genomic rearrangements. Among the samples with a strong kataegis pattern, 
TERT was identified as a differentially expressed gene. To further understand the role of TERT in ChRCC, 
we examined the sequence of the TERT promoter, and identified 3 cases with the previously described 
C228T mutation [184]. In addition, several cases displayed novel genomic rearrangements involving the 
TERT promoter, which were associated with the highest level of TERT expression. These variants were 
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observed with a very high allelic frequency, suggesting TERT-associated rearrangements are early, 
potentially driver events. No equivalent findings have been reported in ccRCC. 
As the first comprehensive molecular analysis of ChRCC, our studies identified several unique 
characteristics of this tumor type, which further reinforce its position as a distinct tumor entity from ccRCC. 
The combination of methylation pattern differences and expression correlations suggest a distal nephron 
cell of origin, while indicating proximal nephron origin of ccRCC. The finding of mtDNA alterations raise 
intriguing questions about the divergent strategies of kidney cells to induce altered metabolism in cancer, 
as our data suggested a complex metabolic phenotype due to more than loss of oxidative phosphorylation.   
Finally, the finding of genomic rearrangements of the TERT promoter suggests alteration of TERT 
expression as a potential driver of this cancer (Figure A.1). These findings were only possible due to the 
integrated analysis of several data types, and the extension of sequencing beyond the confines of the 
exome. The comparison to ccRCC further reinforces the distinct origins and tumorigenic features of these 
cancers, which has important implications for future therapeutic innovations. 
Figure A.0.1: Integrated Analysis identifies key characteristics of Chromphobe Renal Cell Carcinoma 
(ChRCC). ChRCC and clear cell renal cell carcinoma (ccRCC) originate from different regions of the kidney 
nephron. ChRCC is characterized by mitochondrial and TERT alterations. 
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